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Abstract 
Behavioural testing in mouse models of Alzheimer’s disease (AD) suffers from lack of 
standardization and reproducibility issues between laboratories. In order to solve this, a 
touchscreen system has been developed for mice based on the Cambridge 
Neuropsychological Test Automated Battery (CANTAB). There are several cognitive 
dysfunctions that occur due to AD, including deficits in attention that can be tested using 
the touchscreens. In this study, we tested two mouse models of familial AD (5xFAD and 
3xTG) with mutations that lead to an accelerated rate of amyloidosis. Both male and 
female mice were tested at two separate locations in order to test for the reproducibility 
of results. Mice were tested as they aged (4.5, 7, 10 months) in order to establish when 
cognitive symptoms first appear, with the 3xTG line showing deficits at 4.5 months and 
the 5xFAD at 7 months. The results obtained between the two sites were not significantly 
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1 Introduction 
1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting 35 
million people worldwide (Organization, 2012). It is the most common cause of 
dementia, accounting for 60-70% of all cases (Sy et al., 2011). AD affects 1 in 11 people 
over the age of 65 in Canada and these numbers are expected to triple by the year 2050 
(Herbert et al., 2014). 
In ancient times, physicians from the Roman and Greek empires associated old age with 
increased susceptibility to dementia (Berchtold and Cotman, 1998). In 1901, the German 
physician and psychiatrist Alois Alzheimer identified the first case of AD in a fifty-year 
old patient (Greenson, 1987). For most of the 20th century, it was difficult to distinguish 
between dementia and AD, and the diagnosis of AD was reserved for patients exhibiting 
symptoms between the ages of 45 and 65. In 1977, it was concluded that individuals of 
any age that displayed the common characteristic symptoms, disease course and 
neuropathology should be diagnosed with AD, independent of age (Boller and Forbes, 
1998).   
The earliest symptoms of AD include short-term memory loss followed by difficulty with 
language, disorientation, and a variety of behavioural changes in motivation and mood 
(Burns and Iliffe, 2009). As the disease progresses, there is more severe cognitive 
decline, most notably episodic memory, as well as changes in sleep patterns and deficits 
in motor functions (McDonald and Overmier, 1998). In addition, there is severe decline 
  2 
in executive functions; including working memory, sustained attention, task flexibility, 
problem solving and reasoning (Monsell, 2003). 
The pattern of cognitive decline in AD is believed to be the result of neuronal lesions that 
may have been caused by amyloid-beta (Aβ) plaques and tau neurofibrillary tangles 
(NFTs), leading to synaptic loss, and neuronal cell death (Gotz et al., 2004). In addition, 
patients suffering with AD also have vascular lesions. It has been suggested that vascular 
risk factors lead to the dysfunction of the blood-brain barrier and decreasing blood flow, 
hence reducing the clearance of Aβ, leading to a cascade of events preceding dementia 
(Zlokovic, 2011). Nevertheless, the presence of Aβ plaques and tau neurofibrillary 
tangles (NFT) are considered to be the pathological hallmark of AD (Duyckaerts et al., 
2008). 
The average life expectancy of individuals diagnosed with AD is eight to ten years with 
fewer than 4% of people living longer than fourteen years (Molsa et al., 1986, 1995, 
Zanetti et al., 2009). In 68% of all cases, the disease itself is the underlying cause of 
death, usually due to pneumonia and dehydration (Molsa et al., 1986, Ganguli et al., 
2005).  
 
1.2 Neuropathology of AD 
AD is characterized by loss of neurons and synapses in the cerebral cortex and different 
subcortical regions. It is believed that Aβ plaques and NFTs lead to degeneration of 
neurons in the parietal and temporal lobes as well as parts of the frontal cortex (Wenk, 
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2003). Both Aβ plaques and NFTs are clearly visible under microscopy of brains of 
people with AD (Tiraboschi et al., 2004).  
Amyloid plaques are dense, mostly insoluble deposits of amyloid-beta (Aβ40 and Aβ42) 
peptides and cellular material outside of neurons (Tiraboschi et al., 2004). Aβ peptides 
are fragments of the larger amyloid precursor protein (APP), a neuronal transmembrane 
protein critical to neuron survival, growth, and post-injury repair (Priller et al., 2006). 
APP is cleaved by the activity of three proteolytic enzymes: alpha, beta, and gamma 
secretases, however only the latter two give rise to the toxic Aβ peptides (Hartmann et al., 
1997). The Aβ peptides are excised from the larger APP holoprotein through sequential 
scission by the β-APP cleaving enzyme (BACE) and the gamma secretase enzymatic 
complex (Yan et al., 1999).  
Mutations in presenilin-1 (PSEN1) and presenilin-2 (PSEN2), proteins that form the 
catalytic domain of the larger gamma secretase complex (De Strooper et al., 1999, 
Hooper, 2005) lead to AD. Gamma secretase cleaves within the transmembrane domain 
of APP and produces the C-terminal end of Aβ (Hartmann et al., 1997). Aβ peptides are 
known to aggregate to form soluble Aβ oligomers in the extracellular environment and 
these have been shown to be the most toxic form of Aβ (Zhao et al., 2012). In AD, Aβ 
oligomers accumulate and form fibrils which further form clumps around neurons leading 
to dense insoluble formations known as senile plaques (Ohnishi and Takano, 2004, 
Tiraboschi et al., 2004). Plaque deposition normally begins in the basal portions of the 
neocortex, followed by the hippocampus and eventually spreading to subcortical areas 
over time (Braak and Braak, 1991). 
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The second hallmark of AD, NFTs, is caused by the abnormal hyperphosphorylation and 
misfolding of the protein tau (Bouras et al., 1994). Tau is a microtubule-associated 
protein (MAP) that is a major component of a group of MAPs that stabilize microtubules 
and induce its own assembly (Maccioni and Cambiazo, 1995). Microtubules act like 
tracks, guiding nutrients from the cell body to the ends of axons and back. However, 
under pathological conditions, tau becomes hyperphosphorylated causing it to self-
aggregate into paired helical filaments, which eventually aggregate to create the 
neurofibrillary tangles in the intracellular environment (Berger et al., 2007). The 
microtubules are the cytoskeleton for axons and their collapse leads to the disintegration 
of the neuron’s transport system (Hernandez and Avila, 2007). 
Although amyloid plaques and NFTs are associated with AD, it is still not clear how they 
give rise to the neurodegeneration associated with the disease (Huang and Mucke, 2012). 
As discussed in detail in the next section, the amyloid hypothesis points towards the 
accumulation of Aβ peptides as the central event triggering neuronal degeneration. Toxic 
amyloid oligomers disrupt neuronal signaling leading to aberrant calcium ion 
homeostasis and apoptosis (Yankner et al., 1990). In addition, it has been suggested that 
long before the development of senile plaques, Aβ oligomers attach onto the synapse of 
neurons disrupting cell-to-cell communication (Lacor et al., 2007, Zhao et al., 2012). The 
tau hypothesis on the other hand, points towards hyperphosphorylated tau protein as the 
trigger that leads to degeneration of neurons and eventually cell death (Gray et al., 1987). 
Normally, organelles are transported to and from the cell body of a neuron through the 
axon and dendrites, which has a skeleton composed of microtubules (Maccioni and 
Cambiazo, 1995).  Microtubules are stabilized by the tau protein, however in AD, tau 
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becomes hyperphosphorylated and detaches from the microtubules (Iqbal et al., 2005). 
Thus, the skeleton of the neuron dissociates and the defective tau protein form filaments 
that eventually generate the NFTs. Without the microtubule skeleton, and with the 
accumulation of NFTs, neurons degenerate and connections between the neurons are lost. 
This eventually causes the death of the neuron (Chun and Johnson, 2007, Hernandez and 
Avila, 2007). NFTs first develop in the hippocampus, which is essential to memory and 
learning and then spreads to the whole brain in a centrifugal movement causing atrophy. 
The progression of AD symptoms follows the pattern of NFT lesions (Iqbal et al., 2005). 
 
1.3 Genetic Underpinnings of AD 
The cause of most AD cases is unknown except for the cases where genetic mutations 
have been identified. Hence, AD can be classified as two main sub-types: sporadic onset 
AD and familial AD (FAD). Only about 1% to 5% of patients afflicted with the disease 
have the FAD form, whereas the other 95% to 99% have sporadic onset AD (Delacourt et 
al., 2002). Based on family and twin studies, the genetic heritability of AD range from 
49% to 78% and around only 0.1% of familial cases of AD are early onset meaning they 
occur before the age of 65 (Wilson et al., 2011).  
The genetic basis for sporadic onset AD is not well understood. Overall, there are many 
different risk factors that seem to lead to the sporadic form of AD and the genetic 
underpinnings that underlie this form of AD are not immediately obvious. The best-
known genetic risk factor is the inheritance of the ε4 allele of the apolipoprotein E gene 
(APOEε4), and between 40% to 80% of people with AD present at least one APOEε4 
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allele (Strittmatter et al., 1993, Mahley et al., 2006). In addition, the APOEε4 allele 
triples the risk of AD in heterozygotes and increases it by 15 times in homozygotes 
(Blennow et al., 2006). Apolipoproteins have been shown to enhance the breakdown of 
Aβ, however the APOEε4 isoform is not very effective at doing so leading to a build-up 
of Aβ peptides (Polvikoski et al., 1995). Although the APOEε4 allele has been shown to 
increase susceptibility to develop AD, not all individuals with the gene develop the 
disease, and many individuals without the allele develop AD (Selkoe, 2012). For 
example, a study conducted in Nigeria showed no relationship between the APOEε4 and 
onset of AD (Hall et al., 2006). In addition to the APOEε4 allele, there are 19 other 
genetic loci that have been identified to significantly increase the risk of developing AD 
(Lambert et al., 2013). A meta-analysis of genome-wide association study (GWAS) 
conducted by Lambert et. al. in 2013 identified 11 of these genetic loci that increase the 
susceptibility of late-onset AD (Lambert et al., 2013). One of these loci was SORL1, a 
neuronal APOE receptor involved in regulating APP.  SORL1 was found to have reduced 
expression in AD (Scherzer et al., 2004). Other loci identified include PTK2β, an enzyme 
important for calcium-induced regulation of neuronal ion channels and activation of the 
map kinase pathway; FERMT2, a protein that is a component of extracellular matrix 
structures required for control of cell shape; and CLU, a protein associated with the 
clearance of cellular debris and apoptosis (Lev et al., 1995, Jones and Jomary, 2002, Tu 
et al., 2003). In addition, mutations in the triggering receptor expressed on myeloid cells 
2 (TREM2) have also been shown to be associated with a 3-5 times increased risk of AD. 
It has been suggested that due to the TREM2 mutation, microglia cells are no longer able 
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to control the amount of Aβ peptides present in the brain (Guerreiro et al., 2013, Jonsson 
et al., 2013).  
In contrast, FAD is better understood and the genes involved have been identified and 
isolated. Most cases of FAD can be attributed to missense mutations in at least one the 
following three genes: APP, PSEN1 or PSEN2 (Waring and Rosenberg, 2008). There 
have been more than 50 different APP mutations identified, the most common of which is 
the V717I, which replaces the amino acid valine with the amino acid isoleucine at protein 
position 717 (Eckman et al., 1997). The PSEN1 gene, found on chromosome 14, is the 
most common cause of FAD with over 150 different identified mutations. The PSEN1 
gene encodes for the presenilin-1 protein part of the gamma secretase complex (De 
Strooper, 2007). PSEN1 mutations lead to an altered protein that becomes inactive and 
causes gamma secretase to cleave at a different location releasing the longer toxic 
peptides of Aβ (Zahs and Ashe, 2015). These mutations increase the production of toxic 
Aβ peptides that are 42 amino acids in length (Aβ42), and have been shown to be the 
main component of senile plaques. However, a recent study showed mice that are 
homozygous for PSEN1 mutations have complete loss of function of gamma secretase 
and die during the embryonic stage. Mice carrying more than one PSEN1 mutation had a 
decreased production of Aβ, but an increased ratio of Aβ42/Aβ40 that exacerbated Aβ 
deposition (Xia et al., 2015). The ratio of Aβ42/Aβ40 has been previously proposed to 
have important ramifications in the onset of plaques observed in AD, rather than the 
amount of Aβ42 alone (Jarrett et al., 1993).  
One of the most well known mutations of AD is the Swedish FAD mutation occurring on 
the APP gene, originally discovered in 1992 (Mullan et al., 1992). Carriers of this 
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mutation will pass it on to 50% of their offspring who will go on to develop early onset 
AD. This mutation however is extremely rare, only found in two Swedish families and 
never in the general population (Mullan et al., 1992). Similarly the Florida FAD mutation 
was observed in an individual from Florida who had a family history of dementia with an 
average onset of 53 years. Once the mutation was expressed in cell cultures it led to a 
three-fold increase in Aβ42 (Eckman et al., 1997). The London FAD mutation was 
discovered in 1991 in England and was the first described mutation of APP. This 
missense mutation also increases the levels of Aβ42 in many cell types that leads to early 
onset AD (57 years of age approx.) (Goate et al., 1991). 
On the other hand NFTs, the secondary hallmark of AD, caused by the accumulation of 
hyperphosphorylated tau protein, lack genetic evidence linking any FAD tau mutations to 
the onset of the disease (Selkoe, 2011). As a matter of fact, disorders involving a tau gene 
mutation have shown that the development of NFTs alone does not lead to the 
development of Aβ plaques. Hence, it has been suggested that Aβ peptides can lead to the 
development of NFTs, but tangles do not lead to the development of Aβ peptides (Selkoe, 
2011).  
 
1.4 The Amyloid Hypothesis of AD 
The amyloid hypothesis was first introduced in 1991 and builds on the knowledge of the 
genetics of FAD postulating that accumulation of amyloid plaques are the fundamental 
cause for the disease (Hardy and Allsop, 1991). It postulates that Aβ, in a variety of 
forms, triggers a cascade of events that harm synapses and neurons, producing the 
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pathological hallmarks of plaques, NFTs, synapse loss and neurodegeneration, that leads 
to dementia (Hardy and Selkoe, 2002). One aspect of the hypothesis suggests that there is 
a build-up of soluble Aβ oligomers due to the activity of β-secretase and gamma 
secretase on APP, which leads to the insoluble senile plaques (Yan et al., 1999). Some 
researchers have postulated that toxic Aβ oligomers, referred to as amyloid-derived 
diffusible ligands (ADDLs), may be the primary pathogenic form of Aβ. These ADDLs 
bind to neuronal surface receptors and alter the structure of the synapse disrupting cell-to-
cell communication (Lambert et al., 1998, Lacor et al., 2007). The hypothesis is 
supported by the location of the APP gene on chromosome 21. Individuals with an extra 
copy of this chromosome (trisomy 21 – down syndrome) universally exhibit AD by the 
age of 40 (Lott and Head, 2005).  
 
1.5 The Cholinergic Hypothesis of AD 
The cholinergic hypothesis is the oldest postulation of AD. It proposes that AD is caused 
by reduced synthesis of the neurotransmitter acetylcholine (ACh) due to substantial 
deficits in the enzyme responsible for making ACh, choline acetyltransferase (ChAT) 
(Bowen et al., 1976, Davies and Maloney, 1976, Perry et al., 1977). Subsequent 
discoveries of reduced choline uptake, ACh release, and loss of cholinergic neurons in 
the basal forebrain, confirmed a substantial presynaptic cholinergic deficit in AD 
(Whitehouse et al., 1982, Rylett et al., 1983, Nilsson et al., 1986). In addition, at the time, 
research also showed the importance of ACh for cognitive function, such as learning and 
memory (Drachman and Leavitt, 1974). Further support for the hypothesis was provided 
by studies showing strong correlations between the deterioration of the basal forebrain 
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cholinergic system and the occurrence of senile Aβ plaques (Perry et al., 1978, Wilcock 
et al., 1982). However, during the last 20 years, the cholinergic hypothesis has not 
maintained widespread support, mainly because pharmacological interventions intended 
to treat acetylcholine deficiency, seen in AD, have not been very effective (Francis et al., 
1999).  
 
1.6 Current Pharmacological Interventions for AD 
There is no cure for AD, and current pharmacological treatments help delay symptoms 
and maintain cognition for a short period of time. Despite considerable advances in 
knowledge regarding the pathogenesis of AD, no concrete treatments have been 
introduced over the past 25 years (Schneider et al., 2014). There are only five drugs that 
have been marketed for the treatment of AD: four acetylcholinesterase inhibitors (tacrine, 
rivastigmine, donepezil and galantamine), and the NMDA receptor antagonist memantine 
(Schneider et al., 2014). There is a reduction in the release of ACh in AD (Perry et al., 
1977). Acetylcholinesterase inhibitors block the activity of acetylcholinesterase, an 
enzyme found in the synaptic cleft responsible for breaking down ACh, thereby 
increasing the concentration of this neurotransmitter in the brain (Massoulie et al., 1993). 
Evidence suggests that the acetylcholinesterase inhibitors approved for treatment seem to 
have efficacy only in mild to moderate AD and not during the advanced stages of the 
disease (Birks, 2006, Schneider et al., 2014). Therefore, these drugs are only beneficial in 
temporarily delaying the onset of cognitive deficits associated with AD.  
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A review published in 2008 identified 100 AD drug development failures in clinical trials 
(Becker et al., 2008). In the last two decades (since 1991), the focus of AD drug 
development has been on the amyloid hypothesis and the toxic Aβ found in the brain. 
The majority of drugs that were developed for AD attempted to disrupt the activity of the 
proteases, β-secretase and gamma secretase, however none have been successful in 
clinical trials (Becker et al., 2008). Although in theory the amyloid drugs seem simple, 
either by reducing its production through inactivating the enzymes that produce it or by 
increasing its clearance out of the brain, it has been quite complex to implement it in 
practice. One reason for the failure of this approach may be due to differing toxicities of 
various Aβ components. For example, oligomers have been found to be toxic at the 
synapse and Aβ fibrils from plaques may be pro-inflammatory leading neurotoxicity in 
their local environment (Mucke and Selkoe, 2012). Hence, it is unclear whether 
inhibition of Aβ fibril aggregation, inhibition of APP secretases, or antibodies against the 
different forms of Aβ are valid therapeutic strategies (Schneider et al., 2014).   
 
1.7 Development of AD Mouse Models 
As with other slowly progressive diseases, preventing AD depends on understanding the 
early steps in its pathogenesis. For this reason, considerable time and efforts has been 
invested in the development of animal models for AD. Although it accounts for only a 
small portion of AD patients, identifying gene mutations involved with the FAD form of 
the disease greatly enhanced Alzheimer’s research (Selkoe, 2012). Researchers were able 
to create transgenic mice that had the FAD mutations in APP and presenilins that lead to 
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the expression of Aβ plaques similar to those seen in humans (Gotz et al., 2004, 
Schnabel, 2011).  
One of the first AD mouse models generated was the Tg2576 that had the APPSWE FAD 
mutation (Hsiao et al., 1996). The Tg2576 mice showed deficits in spatial working 
memory at 5 months of age in one study, however different methodologies used in 
several other reports failed to reproduce these results (Hsiao et al., 1996, Arendash et al., 
2004). Studies have also shown the Tg2576 mice to have deficits in recognition memory 
at 12 months of age (Oules et al., 2012).  
Another important mouse model of AD was the APP/PS1 mice that had both the APPSWE 
mutation as well as a mutation on PSEN1 that lead to Aβ plaques (Holcomb et al., 1998). 
The first reported deficits in spatial working memory were 6 months of age in the 
APP/PS1 mice, however these were not robust and other reports have failed to reproduce 
these data (Holcomb et al., 1999, Arendash et al., 2001a). Consistent deficits in working 
memory have been reported in the APP/PS1 mice at 15 months of age and deficits in 
recognition memory at 12 months of age (Arendash et al., 2001b, Mori et al., 2013). 
Hence, most of the early mouse models of AD focused on developing the Aβ plaques 
pathology and demonstrated robust cognitive deficits in the later stages of the animal’s 
life. In this thesis we will focus on two models of AD described below that either present 
plaques and NFTs or have high rates of amyloidosis (aggregation of Aβ) and plaque 
formation. 
 
  13 
1.8 The 3xTG Mouse Model of AD 
In 2003, Oddo et al. developed a mouse model of AD that exhibited both Aβ plaques as 
well as tau NFTs called the triple transgenic mouse (3xTG). These mice possess the 
Swedish FAD mutation of APP (APPSWE) as well as a mutation on the presenilin-1 
(PSEN1M146V). In addition, the 3xTG mouse line also has a point mutation on a tau 
transgene (tauP301L) that gives rise to hyperphosphorylated tau protein leading to the 
development of NFTs (Oddo et al., 2003b). The 3xTG mouse line was generated by 
microinjecting the human APPSWE and tauP301L transgenes into the germline of PS1M146V 
knock-in mice. The result was a mouse model that expressed both plaques and tangles 
that increased in severity with age (Oddo et al., 2003b). 3xTG mice express Aβ plaques 
and NFTs in analogous brain regions to that seen in human AD patients, and progression 
of pathology also follows similar patterns to that seen in humans, with plaque deposition 
preceding the development of visible NFTs (Oddo et al., 2003b, Sy et al., 2011).  
The 3xTG mice show no Aβ plaques or NFTs at two months of age (Oddo et al., 2003b). 
However, at this age, other researchers have shown the 3xTG mice to have axonal myelin 
sheath deterioration in the Schaffer Collateral pathway projecting from the hippocampus 
(Desai et al., 2009). The appearance of Aβ pathology occurs first in the neocortex at four 
months of age, however most of the Aβ is in its soluble form at this stage and has not 
started to develop into plaques. At 6 months of age, intraneuronal Aβ is detectable in both 
the amygdala and hippocampal neurons (Oddo et al., 2006a). At approximately 9 months 
of age, there is a decrease in intraneuronal Aβ that is coincident with the development of 
extracellular Aβ plaques in the cortex. These extracellular plaques increase in both size 
and number exponentially with age and by 12-15 months the 3xTG mice show significant 
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Aβ plaques in both the hippocampus and cortex (Oddo et al., 2003b, Oddo et al., 2006a, 
Sy et al., 2011). 
Similarly, AD-like tau pathology also progresses with age in the 3xTG mice. 
Hyperphosphorylated tau protein can first be detected in the CA1 pyramidal neurons of 
the hippocampus at 6 months of age (Oddo et al., 2003a). Levels of abnormally 
phosphorylated tau continue to increase in the hippocampus and by 9 months of age are 
also detectable in the cortex. By the time mice are 10 months of age, 
hyperphosphorylated tau aggregates to form NFTs in both the cortex and hippocampus. 
The density of these NFTs continues to increases exponentially as mice age (Oddo et al., 
2003a, Oddo et al., 2003b). 
The 3xTG mice have been shown to have cognitive deficits in various behavioural 
studies. The 3xTG mice were tested at 2 months of age on the Morris Water maze task 
but showed no deficits (Clinton et al., 2007). However, in a separate study conducted 
using the 8-arm radial maze task to test for working memory, the 3xTG mice did show 
deficits starting at 2 months and onwards until the age of 15 months (Stevens and Brown, 
2015). The first deficits observed in associative learning occur between the age of 3 and 5 
months (Clinton et al., 2007). These are then followed by deficits in spatial working 
memory using the Morris Water Maze task at 6 months of age (Billings et al., 2005, 
Nelson et al., 2007). Deficits in recognition memory have been observed between 9-11 
months of age (Billings et al., 2005, Clinton et al., 2007, Nelson et al., 2007). Also, 
impairments in reference memory were observed in the 3xTG mice using the Barnes 
Maze task at 12 months of age (Nelson et al., 2007). In addition, as discussed in greater 
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detail in the next section, 3xTG males showed deficits in sustained attention when tested 
using touchscreen systems at 10 months of age (Romberg et al., 2011).  
Interestingly, a recent study showed that short-term stress induced a decrease in the 
number of synaptic dendritic spines and increased the levels of Aβ in 3xTG mice, hence 
accelerating amyloid pathology (Baglietto-Vargas et al., 2015). Additionally, it has been 
shown that cholinergic modulation of hippocampal synaptic plasticity is impaired due to 
the PSEN1 mutation in 3xTG mice (Wang et al., 2009). In summary, the neuropathology 
of AD-like plaques and tangles as well as the AD-like cognitive deficits strengthens the 
face validity of the 3xTG as a mouse model of AD.  
 
1.9 The 5xFAD Mouse Model of AD 
Most mouse models of AD, including the above mentioned 3xTG mice, develop 
neuropathological and significant behavioural deficits in the latter stages of life. Although 
this increases the face validity of these mouse models since they recapitulate the late 
onset of AD as seen in humans, it proposes other technical disadvantages such as high 
housing costs for animal facilities, and long delays between planning and performing 
experiments (Bilkei-Gorzo, 2014). For these reasons, a new transgenic mouse line was 
developed by Oakley et al. in 2006 bearing five FAD mutations called the 5xFAD mice, 
that developed AD-like pathology at a much younger age (Oakley et al., 2006). The 
5xFAD mice have three FAD mutations on the APP transgene with the Swedish 
(APPSWE), Florida (APPFL) and London (APPLON) mutations, and two FAD mutations on 
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the presenelin-1 transgene (M146L and L286V). These mutations were introduced into 
mice using the neuron specific Thy1 promoter (Oakley et al., 2006). 
Together, all five of these FAD mutations lead to an accelerated rate of intracellular 
amyloidosis starting at just 1.5 months of age and extracellular Aβ plaques are present at 
2 months in this mouse model. Aβ plaques first appear in layer 5 of the cortex and the 
subiculum at 2 months of age, and spread rapidly to fill the rest of the cortex, subiculum 
and hippocampus by 6 months (Oakley et al., 2006). Due to this rapid amyloidosis, by 9 
months of age, the 5xFAD mice have significant synaptic degeneration and neuron loss 
(Oakley et al., 2006, Bilkei-Gorzo, 2014).   
Multiple studies have observed progressive cognitive deficits with age in the 5xFAD 
mice. This model shows deficits in spatial working memory using the Morris Water Maze 
by 3 months of age (Ohno et al., 2006, Urano and Tohda, 2010). In a study used to test 
for hippocampal-dependent memory deficits using the olfactory tubing maze, 5xFAD 
mice showed deficits beginning at 4 months of age and the deficits increased significantly 
by 6 months (Girard et al., 2014). 5xFAD mice also showed hippocampal-dependent 
spatial working memory deficits when tested using the Y-maze task at 4 months of age 
but not at an age of 2 months (Oakley et al., 2006). Additionally, 5xFAD mice showed 
impairments in associative learning, in fear conditioning, as well as deficits in working 
memory using the Y-maze task (Oakley et al., 2006, Ohno et al., 2006). As seen in 3xTG 
mice, cognitive deficits in recognition memory are observed last in the 5xFAD mice - at 
10 months of age (Tohda et al., 2012). In summary, although 5xFAD mice do not exhibit 
tau NFT pathology like 3xTG mice, they do have an accelerated rate of amyloidosis 
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leading to extensive Aβ plaques and neurodegeneration that contributes to the various 
AD-like cognitive deficits observed.  
 
1.10 Attention Deficits in AD 
Attention is the first non-memory domain affected in AD, before deficits in visuo-spatial 
function and language. It is believed that attention deficits are responsible for the 
difficulties with daily living for patients in the early stages of AD (Bracco et al., 2014). 
Lesion studies in mice have revealed multiple forebrain regions, such as the medial 
prefrontal cortex, anterior cingulate cortex and the parietal cortex, to be essential in 
choice accuracy for mice (Muir et al., 1996). Brain correlates for attention in humans has 
been shown to be in similar regions, mainly the frontal and parietal cortices (Pepeu et al., 
2013). In terms of neurotransmitter systems involved in attentional control, major 
findings over a 20-year period, have shown selective lesions in the monoaminergic 
(noradrenergic, dopaminergic and serotoninergic) and cholinergic systems to cause the 
greatest deficits (Robbins, 1997, Pepeu et al., 2013). Since arousal and attention depend 
on activation of the forebrain cholinergic system, it is to be expected that the loss of 
cholinergic neurons occurring in AD may lead to impairment of the attentional processes 
(Pepeu et al., 2013). Improvement of attention following cholinesterase inhibitors, such 
as donepezil, administration has been demonstrated in mouse models of AD (Romberg et 
al., 2011). In addition, cholinesterase inhibitors have been shown to improve global 
cognitive measures in AD and attenuate the neuropsychiatric symptoms through a 
primary effect on the cholinergic neurons involved in regulating attention (McGuinness 
et al., 2010, Pepeu et al., 2013).  
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1.11 CANTAB Touchscreen Systems 
Despite over thirty years of research on AD and numerous potential treatments that were 
tested in clinical trials, there have been no drugs that have been able to halt or reverse the 
progression of the disease (Selkoe, 2012, Schneider et al., 2014). There have been many 
pharmacological interventions that have shown promise in pre-clinical animal studies of 
AD, but have failed to translate the same results in the clinic (Schneider et al., 2014). One 
critical issue that has been identified for this lack of translatability is the difference 
between tests of cognition used for mice in pre-clinical research and those used in 
humans with AD (Romberg et al., 2013a). The Cambridge Neuropsychological Test 
Automated Battery (CANTAB) has been used to assess cognitive dysfunctions in 
neuropsychiatric and neurodegenerative disorders including AD and mild cognitive 
impairment (Junkkila et al., 2012). Based on the CANTAB battery, a touchscreen system 
has been developed by Tim Bussey, Lisa Saksida and colleagues, to make behavioural 
cognitive tests in rodents more standardized, automated and increase the translational 
potential of research in mouse models (Bussey et al., 2008).  
The first advantage of using the touchscreen systems to test for cognitive deficits in mice 
is that they are automated. Having an automated behavioural test reduces the amount of 
labour required and allows researchers to test multiple mice simultaneously. Moreover, 
an automated behavioural test such as these touchscreens allows researchers to 
profoundly reduce the interaction between animals and the experimenter eliminating 
confounds that this interference might entail during testing (Bussey et al., 2012). Human 
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interference during behavioural testing can have huge effects, not only by introducing 
variability in the way the test is run, but also by potential confounds in the way each 
experimenter handles the animals, or even the sight and smell of the experimenter 
(Wahlsten et al., 2003). In addition, since a computer controls the touchscreen systems, 
many parameters including stimulus presentation and delays are identical every time for 
each animal and all measures of the test are then collected by the computer making it 
possible to collect data down to the exact millisecond (Bussey et al., 2012). The use of a 
computer-controlled system also allows for the collection of multiple parameters at once 
such as accuracy, omissions, and latencies to name a few. Overall, due to their 
automation, the touchscreen systems might be more reliable than non-automated 
behavioural tests such as mazes. 
The second advantage of using touchscreen systems is that they cause low stress to the 
animals. It is important to avoid unnecessary stress when testing for cognitive deficits in 
diseases such as AD. The touchscreen systems used in this study are reward based, rather 
than aversive thus reducing the amount of stress an animal might encounter (Bussey et 
al., 2012).  
Finally, the main advantage of using touchscreen systems is their translatability. By 
creating the same tasks for mice as the CANTAB, researchers can test for the same 
cognitive domains that are tested in humans with AD and other mild cognitive disorders 
(Bussey et al., 2012). Currently the tests used in animals, such as the Morris water maze, 
are usually nothing like those we use in clinical populations; i.e. humans who are old and 
might be suffering from AD do not have their working memory tested in a swimming 
pool with a hidden platform like mice tested in the Morris water maze task. This creates a 
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huge disconnect when promising results found in animal research do not translate into the 
same outcomes in the clinic (Bussey et al., 2012). By using the touchscreen systems that 
are as similar as possible to human tests, this study aims to increase the face validity of 
behavioural testing and increase the translational effectiveness of future studies in the 
clinic.   
The touchscreen systems can be used in various different rodent tasks to test for deficits 
in learning and memory, executive function, working memory, and pattern separation. 
For learning and memory, there are a number of different tasks that can be used on the 
touchscreen systems. The visual discrimination (PD) task is relatively simple and used to 
test whether animals can distinguish between two different stimuli with one being the 
conditioned stimulus (CS+) that is rewarded compared to the second stimulus (CS-) 
(Horner et al., 2013). In the paired-associate learning (PAL) task, the correct stimulus is 
identified by the combination of the stimulus itself and spatial location on the screen 
(Horner et al., 2013). The visuomotor conditional learning (VMCL) task requires the 
animal to identify the conditional visual stimulus that is presented and answer correctly 
(left or right) (Horner et al., 2013).  
For testing executive functions, Bussey and his colleagues have described several other 
tasks that can be utilized on the touchscreen systems. First, extinction learning can be 
used to assess the rate and extent of curtailing a stimulus that was previously associated 
with a reward but no longer is (Mar et al., 2013). Secondly, reversal learning can be 
testing using the PD task by switching the CS+ stimulus with the CS- stimulus and 
measuring the rate it takes an animal to extinguish the initial task and learn the new one 
(Mar et al., 2013).  
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Lastly, the 5-Choice Serial Reaction Time Task (5-CSRTT) can be used in order to test 
for the ability of an animal to selectively detect and respond to spatially unpredictable 
visual stimuli (Mar et al., 2013). The original development of the 5-CSRTT was based on 
the continuous performance test designed by Rosvold and Mirsky in a nine-hole operant 
chamber, used to test sustained and divided attention (Beck et al., 1956). Many early 
attempts to examine attention control in animals used this nine-hole box (Carli et al., 
1983). Rodents had to monitor the occurrence of a brief target stimulus (light) in one of 
five holes at the back of the box, detected by a nose-poke response monitored by infrared 
photocell beams, and correct responses rewarded by a food pellet in the magazine tray at 
the rear of the chamber (Robbins, 2002). The task was essentially designed to test the 
ability of the rodent to sustain spatial attention divided amongst a number of locations 
over a number of trials and this is measured by the accuracy of the total number of 
correct trails (Robbins, 2002). Difficulty in the 5-CSRTT can be varied by adjusting the 
brightness of the stimuli, adding distracting stimuli such as bursts of white noise or 
presenting visual stimuli in locations not associated with the test (Robbins, 2002). The 5-
CSRTT used in the present study utilized the Bussey touchscreen chambers to present 
rodents with 5 spatial locations on a screen in order to test attentional demand at various 
stimulus lengths (Mar et al., 2013).  
 
1.12 Objectives of this Study 
Hypothesis: Attention deficits are common behavioral abnormalities in mouse models of 
AD. The 3xTG and 5xFAD mouse models will both show attentional deficits using the 5-
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CSRTT. The appearance of the phenotype will vary depending on the severity of AD 
pathology for each model.  
Rationale: Attentional control, part of the overall executive functions, declines during the 
early stages of AD (Baddeley et al., 2001). Like memory, attention is controlled by 
multiple cortical and subcortical regions in the brain (Duncan, 2006). Although AD is 
most commonly known as a memory disorder due to the loss in episodic memory, deficits 
in sustained attention and executive functions occur earlier in the disease and are usually 
overlooked by patients (Artero and Ritchie, 2003). The deficits in executive control 
(including attention) precede impairments in language, spatial and long-term memory 
(Bentley et al., 2008). Hence, understanding the nature of attention deficits that occur 
early in AD may provide insights into the mechanism and lead to potential 
pharmaceutical interventions that can be applied before the disease further advances.  
Aim 1: The first aim was to test the 3xTG and 5xFAD mouse models of AD for attention 
deficits as they age, using the 5-CSRTT. Multiple cognitive domains are compromised in 
AD. Deficits in executive functioning and sustained attention occur during the early 
stages of AD (Romberg et al., 2013a). Understanding the characteristics of attention 
deficits in AD can help detect the disease during its early stages before it progresses. The 
3xTG and 5xFAD mouse lines were selected for this study as they have the fastest 
progression of AD-like pathology and cognitive symptoms and would be ideal candidates 
for future studies in order to test for potential therapeutic interventions. In this study, we 
proposed to determine if and when each mouse line develops deficits in sustained 
attention. Male 3xTG mice were previously tested using the 5-CSRTT by Romberg et. al. 
in 2011 and were shown to have deficits at 10 months of age (Romberg et al., 2011). 
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However, as mentioned above, the 3xTG mice develop plaques and tangles earlier and 
have shown to have cognitive deficits between 3-5 months of age (Clinton et al., 2007). 
In addition, the 5xFAD mice have been shown to have Aβ plaques at 2 months of age and 
working memory deficits present at 3 months of age (Oakley et al., 2006, Ohno et al., 
2006, Urano and Tohda, 2010). Hence, in this longitudinal study, both mouse lines were 
tested multiple times on the 5-CSRTT as they aged (4.5, 7, 10 months) in order determine 
when attention deficits first appear and whether these deficits get progressively worse 
with age.  
Aim 2: The second aim of this study was to determine whether data are reproducible 
when the 5-CSRTT is run at two different sites. Traditional cognitive behavioural testing 
in mouse models is subject to extreme variation (Wahlsten et al., 2003). There are 
multiple reasons as to why this occurs including the use of distinct protocols used by 
different labs, and experimenter error or bias due to lack of automation (Landis et al., 
2012, Button et al., 2013). The touchscreen systems used in this study were designed to 
overcome these impediments. Reproducibility of data is key in cementing the touchscreen 
systems as a valid behavioural paradigm in order to determine cognitive deficits in mice.  
However, this has not yet been tested systematically. Thus, this study tested both the 
3xTG and 5xFAD mice at the University of Western Ontario and at Dr. Boyer Winters’ 
laboratory at the University of Guelph simultaneously (experiments conducted by Daniel 
Palmer). 
Aim 3: The last aim of this study was to determine whether there are sex differences in 
the 3xTG and 5xFAD mouse models of AD. For humans, almost two-thirds of 
individuals affected with the disease are women, suggesting females are 
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disproportionately affected by AD (Bennett, 2007). The primary explanation for this is 
due to the fact that women live longer and AD occurs during the latter stages of life 
(Seshadri et al., 1997, Bennett, 2007). However, many age-specific studies conducted 
have not been able to find any significant conclusions that age is the reason why women 
have a higher prevalence for AD (Seshadri et al., 1997, Hebert et al., 2001). Hence, there 
is no evidence that women are more likely to develop AD than men at any given age. 
Thus, the study conducted here tested both male and female mice for the 3xTG and 
5xFAD mice in order to determine whether there is any difference in the onset and 
progression of cognitive deficits. To the best of my knowledge, this is the first time 
female mice were tested on the touchscreen systems.   
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2 Materials and Methods 
2.1 3xTG Mice 
The 3xTG mice (B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa) and age-matched 
control mice (B6129SF2/J) used in this study were all bred at the Jackson Laboratory in 
Bar Harbor, Maine, and shipped to Canada for behavioural testing. In summary, the 
3xTG mice were homozygous for three mutations (PSEN1, APPSWE, and tauP301L) (Oddo 
et al., 2003b). The wild-type control mice were generated by crossing C57BL/6J females 
(B6) and 129S1/SvImJ males (129S) in order to create the B6129SF2/J mice.  
The mice used in the present study, twelve 3xTG males, twelve 3xTG females, twelve 
B6129SF2/J wild-type control males and twelve B6129SF2/J wild-type control females, 
were three months of age at the start of behavioural testing. At this age 3xTG mice 
exhibit few or no extracellular Aβ deposits and relatively low levels of 
hyperphosphorylated tau (Nelson et al., 2007, Hirata-Fukae et al., 2008).  
 
2.2 5xFAD Mice 
The 5xFAD mice (B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/J) and 
age-matched wild-type controls (B6SJLF1/J) were also bred at the Jackson Laboratory in 
Bar Harbor, Maine, and shipped to Canada for behavioural testing. The mice used in the 
present study, twelve 5xFAD males, twelve 5xFAD females, twelve B6SJLF1/J wild-
type control males, and twelve B6SJLF1/J wild-type females, were three months of age at 
the start of behavioural testing.  The 5xFAD mice have previously demonstrated to have 
intraneuronal Aβ present starting at 1.5 months of age (Oakley et al., 2006). 
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2.3 Housing and Food Restriction 
Mice of the same genotype and sex were housed in groups of 2, in a room with a 12-hour 
light/dark cycle (lights turn off at 7:00 P.M.). All behavioural testing was conducted 
during the light phase of the cycle. Mice were maintained on a restricted diet and kept at 
85% of adult baseline body weight during the experiment. This was done in order to 
ensure the animals were motivated to perform the behavioural touchscreen tasks. All 
mice were put on food restriction one week prior to the start of behavioural testing and 
the body weights were gradually lowered to 85% of the original weight. 
To determine the weight curve of a typical mouse as it ages, mouse weights of wild-type 
mice at various ages, ranging from pups to adult mice were recorded (Figure 1). Based 
on these weight curves for both male and female mice (Figure 1), we determined the 
ideal 85% body weight for males should be 23.0 grams and females 20.0 grams, at the 
start of behavioural training. Once body weight was reduced to 85% of baseline for an 
individual mouse, it was safely maintained throughout the testing period by providing 
2.5g of food per day for males and 2.0g of food per day for females (Tekland Chow – 
Harlan). Mice were weighed every other day in order to ensure maintenance of body 
weight at 85% of original weight. Water was available ad libitum throughout the 
experiment.  
There was a criteria established in the SOP to drop any mouse that does not acquire the 
ability to perform on the touchscreen systems during training. Data from mice that did 
not survive or were dropped due to lack of performance was not included in the final 
figures. 




Figure 1. Male and female wild-type weight according to age. Behavioural testing 
commenced when the mice were 12 weeks of age. Based on these weight curves it was 
determined the 85% baseline body weight for males was 23.0g and females 20.0g, in 
order to ensure motivation. (Data are mean ± SEM).  
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2.4 Touchscreen Apparatus 
Behavioural testing was conducted in the automated Bussey-Saksida Touchscreen 
System model 81426 (Campden Instruments) for mice (Figure 2). The apparatus 
consisted of a testing chamber housed within a sound and light-attenuating box (40 by 34 
by 42 cm). The inner operant chamber consisted of a stainless steel grid floor, black 
plastic walls, and a clear plastic cover for the top. The operant chambers were fitted with 
a fan for ventilation and masking of extraneous noise and a reward tray that dispenses 
liquid reward through a pump. At the other end of the chamber, opposite to the reward 
tray, was a LCD monitor equipped with an infrared touchscreen controlled system by 
ABET II Touch software v.3.1 (Lafayette Instruments). A black plastic cover with 5 
small response windows (2cm by 2cm) was placed in front of the monitor in order to 
reduce unintended responses by the tail or other body parts of the mouse (Figure 2). The 
operant chambers were also equipped with a house light and a tone generator. All 5-
CSRTT schedules were designed and data were collected using the ABET II software. 
 
2.5 Shaping 
Mice were trained to operate the touchscreens by a series of shaping procedures (Figure 
3) (Mar et al., 2013). All schedules used during the training for the 5-CSRTT were pre-
installed by the ABET II software. Please refer to the appendix attached for a more 
detailed operating procedure for the 5-CSRTT. For the first four days, animals were 
habituated to the testing chambers using the Habituation schedules. On the first day 
(Habituation 1), the mice remained in the testing chambers for 10 minutes, the house 
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lights were off, and there were no touchscreen stimuli or strawberry milkshake reward 














Figure 2: Photograph of the touchscreen chambers. On one side of the chamber 
is the touchscreen monitor covered by a black plastic mask with 5 small windows 
(2 cm by 2 cm). On the opposite side of the chamber is the reward tray where 
strawberry milkshake is dispensed. The entire operant chamber is enclosed within 
a sound and light-attenuating box.  
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Figure 3 
Figure 3: Flow chart of the 5-CSRTT schedules. On the left, all schedules pertaining to 
the training phase of the touchscreen systems. On the right, training in the 5-CSRTT itself 
with the 4 seconds, 2 seconds, and probe trial schedules last. Each schedule also includes 
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two days (Habituation 2a), the mice were placed into the testing chambers for 20 minutes. 
During this phase, the reward tray light was turned on and primed with strawberry 
milkshake (150µl) along with a tone. The light remained on until the mouse entered the 
reward tray and turned back on 10 seconds after the mouse left the tray where more 
milkshake was provided (7µl) along with a tone. During the last day of habituation 
(Habituation 2b), the mice were placed in the testing chambers for 40 minutes and were 
subjected to the same schedule as the previous two days. Again, in this phase the mice 
further strengthened the association of the reward tray light and tone with a small 
milkshake reward (7µl).  
Following the habituation, the mice were subjected to the initial touch schedule (one day, 
30 trials). A single stimulus (a white square box, 2 cm × 2 cm) was randomly displayed 
in 1 of the 5 response windows. After 30 seconds, the stimulus disappeared, the 
illumination of the reward tray light coinciding with a tone, and the delivery of 
strawberry milkshake reward (7µl). Once the mouse collected the milkshake, the reward 
tray light extinguished and the next trial commenced after a 5 seconds inter-trial interval 
(ITI; houselight off, reward tray inactive, no stimulus presented). A response to the 
stimulus on the screen was rewarded with the delivery of a tone and three times the 
amount of strawberry milkshake (21µl). Training continued on the initial touch schedule 
until the mice completed 30 trials within 60 minutes.  
During the next schedule, called must touch, the stimulus remained on the screen until the 
mouse touched the correct response window, which resulted in reward of strawberry 
milkshake (7µl), illumination of the tray light, and a tone. The collection of the milkshake 
triggered the 5 seconds ITI after which the next trial commenced, and a new stimulus was 
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presented in 1 of the 5 response windows. Each animal continued training until it 
completed 30 trials within 60 minutes.  
The next stage of shaping introduced the animals to the initiation procedure, a schedule 
called must initiate. At the beginning of each trial, the reward tray was illuminated, and 
the animal was required to initiate the stimulus delivery by a nose poke into the reward 
tray. Successful initiation was indicated by the extinction of the tray light and the 
subsequent display of a stimulus. After touching the stimulus and collecting the reward, 
the mouse was subjected to the 5 seconds ITI before the illumination of the reward tray 
light indicated the beginning of the next trial. Once animals readily initiated trials and 
completed 30 trials within 60 min they moved onto the last shaping phase.  
During the last shaping stage, the mouse learns to both initiate and touch the touchscreen 
stimulus in its correct location. This schedule is similar to the previous must initiate 
schedule, however, if a mouse touches an incorrect (non-illuminated) location on the 
screen, the house lights will be turned on for 5 seconds and no reward is given. This is 
followed by the regular 5 seconds ITI period prior to the start of the next trial. The mice 
continue to do this phase of shaping until they are able to obtain at least 23 out of 30 
trials correct within 60 minutes, on two consecutive days. Once the mice passed the 
punish incorrect schedule, they went on to train in the 5-CSRTT itself.  
 
2.6 5-CSRTT Training 
Mice were trained to respond to brief flashes of light pseudo randomly displayed in one 
of the five response windows on the touchscreen. Mice were tested 5 days a week, 50 
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trials or 60 minutes a day. Each trial began with the illumination of the reward tray that 
elicited a nose poke from the mice. The stimulus was then displayed in one of the 
response windows pseudo randomly after a 5 to 10 seconds variable delay instead of an 
immediate presentation of the stimulus as in the previous shaping schedules. If a mouse 
prematurely touched the screen during this delay, the response was recorded as premature 
and the mouse was punished with a 5 seconds time out (houselight on, reward tray 
inactive). This was followed by a 5 second ITI (houselight off, reward tray inactive), after 
which the illumination of the reward tray light signaled the onset of the next trial (Mar et 
al., 2013). The touchscreen stimulus duration was initially set to 4 seconds, followed by a 
limited holding period of 5 seconds, during which the animal was still able to respond to 
the location where the stimulus appeared. Responses during stimulus presence or the 
limited holding period were recorded either as correct (stimulus window) or incorrect 
(any other window). A correct choice was rewarded with a tone and the illumination of 
the tray light, and strawberry milkshake delivery (7µl). Reward collection turned the 
reward tray light off and triggered the 5 seconds ITI. An incorrect response was punished 
with a 5 seconds time out (houselight on, reward tray inactive), followed by a 5 seconds 
ITI (Mar et al., 2013). Failure to respond to any window by the end of the limited holding 
period was recorded as an omission and punished with a 5 seconds time out, followed by 
the 5 seconds ITI before the start of the next trial. The mice continued on the 4 seconds 
stimulus duration until performance was stabilized greater than 80% accuracy, less than 
20% omissions for 3 consecutive days. Once the mice had passed these criteria, the 
stimulus duration was reduced to 2 seconds. After reaching the same criterion with the 2 
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seconds stimuli (<80% accuracy, >20% omission, for 3 consecutive days), the mice were 
tested on the four 5-CSRTT probe trial schedules (Mar et al., 2013). 
2.7 5-CSRTT Probe Trials 
After completing training on the 5-CSRTT 2 seconds stimulus duration, the mice were 
challenged by reducing the stimulus duration to 1.5, 1.0, 0.8 and 0.6 seconds. At this 
shorter stimulus duration, the mice required increased attention demand in order to 
successfully complete the task. The sequence of stimulus duration was presented 
randomly to each mouse in order to control for order effects. Each mouse performed 2 
consecutive days at a given probe trial stimulus duration (1.5s, 1.0s, 0.8s, or 0.6s), and 
was then moved back onto a 2 seconds stimulus duration for 2 days before they were 
subjected to the next probe. The mice continued on the probe trials until they had 
completed all four, taking a total of 14 days.  
2.8 Longitudinal Testing 
Mice were tested as they aged at three separate time points. The first probe trials were 
completed when the mice were 4-5 months of age. After the completion of the first set of 
probe trials, all mice were kept on a maintenance schedule (2 seconds stimulus duration) 
at least once a week until the commencement of the second set of probe trials that started 
at 7 months of age. This was to ensure that the mice did not lose the ability to use the 
touchscreen systems and hence would not require retraining prior to the subsequent 7 and 
10-month probe trials. Upon the completion the second set of probe trials, the mice were 
put back on a weekly 2 seconds maintenance schedule until the commencement of the 
third set probe trials at 10 months of age.  
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2.9 Touchscreen Parameters 
The ABET II software automatically collected the following parameters throughout the 
training and probe trial schedules in order to assess 5-CSRTT performance:  
• Accuracy: number of correct responses divided by the sum of correct and 
incorrect responses (# correct /(# correct + # incorrect) × 100). Accuracy is the 
main measure of sustained attention in this task.  
• Omission: number of omissions divided by total number of trials.  
• Premature Responses: total number of responses during the 5 seconds ITI divided 
by the total number of trials. Premature responses reflect impulsivity in this task. 
• Perseverative Correct: total number of nose pokes in the reward tray after a 
correct response, but before collection of the reward, divided by the total number 
of trials. This is a measure of compulsivity/cognitive inflexibility in this task. 
• Correct Response Latency: average time it takes for the mouse to touch the screen 
after the onset of the stimulus. The correct response latency reflects cognitive 
processing speed in this task.  
• Reward Collection Latency: average time taken after a correct response to the 
collection of the milkshake reward from the reward tray. 
Statistical Analysis: All stats were performed using Graphpad Prism 6.0 software. 
Comparisons between experimental groups were made by either a Student’s t-test or two-
way ANOVA with repeated measures. For that, the data passed normal distribution tested 
by the software. When appropriate a Tukey’s post hoc comparison test was used. In all 
comparisons, p < 0.05 was considered statistically significant and all data are expressed 
as mean ± SEM.  
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3 Results 
3.1 Training of 3xTG and 5xFAD mice in the 5-CSRTT 
The performance of both the 3xTG and 5xFAD males and females did not differ from 
that of control mice for touchscreen operation training (pre-training phases). The number 
of trials (days) required to reach criteria across all pre-training phases did not differ 
between genotypes. Similarly, when mice were trained to respond to flashes of light 
displayed in one of the five spatial locations on the touchscreens (training phase), 
performance of 3xTG males did not differ from that of controls in reaching criteria during 
the 5-CSRTT training schedules of 4 seconds and 2 seconds (Figure 4A; 4 seconds: t(22) 
= 0.7002, p = 0.4912; 2 seconds: t(18) = 1.456, p = 0.1625). Interestingly, 3xTG female 
mice showed a significantly worse performance compared to controls during the 2 
seconds schedule, needing more sessions to reach criteria, but were not different during 
the 4 seconds schedule (Figure 4B; 4 seconds: t(19) = 0.3997, p = 0.6938; 2 seconds: t(19) 
= 0.2.121, p = 0.0473). In contrast, performance of both males and females 5xFAD mice 
did not differ from that of controls during the 4 seconds and 2 seconds training schedules 
(Figure 4C; 4 seconds: t(22) = 0.3347, p = 0.7410; 2 seconds: t(22) = 0.0325, p = 0.9744; 
Figure 4D; 4 seconds: t(21) = 0.6643, p = 0.5137; 2 seconds: t(21) = 0.9467, p = 0.3546).  
3.2 Attention Capacity of 3xTG Male Mice 
We investigated the performance in the 5-CSRTT for 3xTG mice longitudinally to fully 
capture age-dependent deficits that are triggered by AD-like pathology. Based on  
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Figure 4: Trials to reach criteria in the 5-CSRTT for the 2 seconds and 4 seconds 
training schedules. A, 3xTG males and age-matched WT controls. B, 3xTG females 
and age-matched WT controls. C, 5xFAD males and age-matched WT controls. D, 
5xFAD females and age-matched WT controls. (All data are ± SEM, *p<0.05). 
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pathology accumulation and previous behavioural experiments (Romberg et al., 2011), 
we chose 4.5, 7 and 10 months to study 3xTG AD-mice. 
Male 3xTG demonstrated deficits in accuracy, the main measure of attention in the 5-
CSRTT, compared to age-matched control mice with an overall genotype difference in 
accuracy at 4.5 months (Figure 5A; RM-ANOVA, main effect of genotype, F(1,17) = 
9.842, p = 0.0060; main effect of stimulus duration, F(3,51)  = 25.55, p < 0.0001; no 
interaction effect, F(3,51) = 0.8163, p = 0.4908). Compared to age-matched controls, 4.5 
month old male 3xTG mice did not show a difference in omissions when compared to 
controls (Figure 5B; RM-ANOVA, no effect of genotype, F(1,17) = 0.0018, p = 0.9663; 
main effect of stimulus duration, F(3,51)  = 22.88, p < 0.0001; no interaction effect, F(3,51) = 
0.4374, p = 0.7272). However, transgenic mice presented a difference in correct response 
latency, a measure of cognitive processing speed, when compared to controls (Figure 
5C; RM-ANOVA, main effect of genotype, F(1,17) = 11.10, p = 0.0040; main effect of 
stimulus duration, F(3,51)  = 2.804, p = 0.049; no interaction effect, F(3,51) = 0.4679, p = 
0.7059). There is no difference between genotypes for premature responses (Figure 5D; 
RM-ANOVA, no effect of genotype, F(1,17) = 2.228, p = 0.1538; no effect of stimulus 
duration, F(3,51)  = 1.354, p = 0.2673; no interaction effect, F(3,51) = 0.3297, p = 0.78039), 
number of perseverative correct responses (Figure 5E; RM-ANOVA, no effect of 
genotype, F(1,17) = 0.0828, p = 0.7770; main effect of stimulus duration, F(3,51)  = 3.506, p 
= 0.0218; no interaction effect, F(3,51) = 1.883, p = 0.1441), or reward collection latency 
(Figure 5F; RM-ANOVA, no effect of genotype, F(1,17) = 1.351, p = 0.2621; no effect of 
stimulus duration, F(3,51)  = 0.7123, p = 0.5492; no interaction effect, F(3,51) = 1.165, p = 
0.3321).  
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Figure 5: Performance and response measures of 4.5 month-old 3xTG Males 
tested at University of Western Ontario during the 5-CSRTT probe trials. Mice 
were subject to a series of probe trial schedules and the average values of the sessions 
are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. 
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward 
collection latency (3xTG males n=11, WT males n=8, data are mean ± SEM, 
**p<0.01) 
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At 7 months, male 3xTG mice showed a difference in accuracy compared to age-matched 
control littermates (Figure 6A; RM-ANOVA, no effect of genotype, F(1,17) = 4.385, p = 
0.0516; main effect of stimulus duration, F(3,51)  = 26.74, p < 0.0001; main interaction 
effect, F(3,51) = 3.092, p = 0.0351) and post-hoc analysis revealed that they had a 
significantly lower accuracy at the 0.6s stimulus duration during the probe trials (Fig. 
6A). Similarly to the 4.5 month-old transgenic mice, there were no differences between 
3xTG and controls in omissions (Figure 6B; RM-ANOVA, no effect of genotype, F(1,17) 
= 0.5091, p = 0.4852; main effect of stimulus duration, F(3,51)  = 26.35, p < 0.0001; no 
interaction effect, F(3,51) = 0.1061, p = 0.9562). The 7 month old transgenic males also 
had significantly higher correct response latencies when compared to age-matched 
controls (Figure 6C; RM-ANOVA, main effect of genotype, F(1,17) = 9.434, p = 0.0069; 
main effect of stimulus duration, F(3,51)  = 4.252, p = 0.0093; no interaction effect, F(3,51) = 
0.5739, p = 0.6348). There was no difference between genotypes in premature responses 
(Figure 6D; RM-ANOVA, no effect of genotype, F(1,17) = 2.076, p = 0.1677; main effect 
of stimulus duration, F(3,51)  = 3.532, p = 0.0211; no interaction effect, F(3,51) = 0.2442, p = 
0.8651), perseverative correct responses (Figure 6E; RM-ANOVA, no effect of 
genotype, F(1,17) = 0.4685, p = 0.5029; main effect of stimulus duration, F(3,51)  = 4.866, p 
= 0.0047; no interaction effect, F(3,51) = 0.7868, p = 0.5068), or reward collection latency 
(Figure 6F; RM-ANOVA, no effect of genotype, F(1,17) = 0.9133, p = 0.3526; no effect of 
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Figure 6. Performance and response measures of 7 month-old 3xTG Males at the 
University of Western Ontario during the 5-CSRTT probe trials. Mice were 
subject to a series of probe trial schedules and the average values of the sessions are 
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D, 
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG males n=11, WT males n=8, data are mean ± SEM, **p<0.01)  
Accuracy
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Ten month old 3xTG males showed both a genotype and interaction difference in 
accuracy compared to age-matched controls (Figure 7A; RM-ANOVA, main effect of 
genotype, F(1,13) = 5.261, p = 0.0391; main effect of stimulus duration, F(3,39)  = 19.81, p < 
0.0001; main interaction effect, F(3,39) = 4.661, p = 0.0071). Post-hoc analysis revealed 
that they had significantly lower accuracy at the 0.6s stimulus duration during the probe 
trials (Fig. 7A). Moreover, the 10 months old 3xTG males also presented a difference in 
omissions during the task when compared to controls (Figure 7B; RM-ANOVA, main 
effect of genotype, F(1,13) = 9.371, p = 0.0091; main effect of stimulus duration, F(3,39)  = 
16.91, p < 0.0001; no interaction effect, F(3,39) = 2.4111, p = 0.0815). Male 3xTG mice 
also had a significant difference in correct response latency at this age (Figure 7C; RM-
ANOVA, main effect of genotype, F(1,13) = 4.709, p = 0.0491; no effect of stimulus 
duration, F(3,39)  = 0.5234, p = 0.6687; no interaction effect, F(3,39) = 0.3645, p = 0.7790). 
In contrast, the 10 month old 3xTG mice did not reveal a difference in premature 
responses between the two genotypes (Figure 7D; RM-ANOVA, no effect of genotype, 
F(1,13) = 0.1053, p = 0.7507; no effect of stimulus duration, F(3,39)  = 1.057, p = 0.3782; no 
interaction effect, F(3,39) = 1.760, p = 0.1708). Perseverative correct, which reflects 
compulsivity, was different between genotypes (Figure 7E; RM-ANOVA, main effect of 
genotype, F(1,13) = 5.649, p = 0.0335; no effect of stimulus duration, F(3,39)  = 1.676, p = 
0.1880; no interaction effect, F(3,39) = 0.4492, p = 0.7193). Lastly, reward collection 
latency was not different between genotypes (Figure 7F; RM-ANOVA, no effect of 
genotype, F(1,13) = 0.9227, p = 0.3543; no effect of stimulus duration, F(3,39)  = 1.678, p = 
0.1876; no interaction effect, F(3,39) = 1.621, p = 0.2000). 
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Figure 7. Performance and response measures of 10 month-old 3xTG Males at 
the University of Western Ontario during the 5-CSRTT probe trials. Mice were 
subject to a series of probe trial schedules and the average values of the sessions are 
plotted. Mice were subject to a series of probe trials and the average values of the 
sessions are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response 
latency. D, Mean premature responses. E, Mean perseverative correct. F, Mean reward 
collection latency (3xTG males n=8, WT males n=7, data are mean ± SEM, *p<0.05 
and **p<0.01)  
Accuracy
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3.3 Attention Capacity in 3xTG Female Mice 
We also investigated the performance of female 3xTG mice longitudinally in the 5-
CSRTT. Similar to males, female 3xTG mice also revealed differences in both accuracy 
and correct response latencies throughout all three probe trials.  
The 4.5 month old 3xTG females showed decreased accuracy compared to controls 
(Figure 8A; RM-ANOVA, main effect of genotype, F(1,18) = 4.523, p = 0.0475; main 
effect of stimulus duration, F(3,54)  = 18.79, p < 0.0001; no interaction effect, F(3,54) = 
1.593, p = 0.2017) and increased omissions (Figure 8B; RM-ANOVA, no effect of 
genotype, F(1,18) = 3.604, p = 0.0738; main effect of stimulus duration, F(3,54)  = 69.94, p < 
0.0001; main interaction effect, F(3,54) = 2.936, p = 0.0414). Post-hoc analysis revealed a 
significant increase in omissions at the 0.6s stimulus duration (Fig. 8B). In addition, the 
transgenic females showed both a genotype and interaction difference in correct response 
latency (Figure 8C; RM-ANOVA, main effect of genotype, F(1,18) = 12.44, p = 0.0024; 
no effect of stimulus duration, F(3,54)  = 1.490, p = 0.2276; main interaction effect, F(3,54) = 
3.772, p = 0.0157) with post-hoc analysis revealing a significant increase in latency at the 
0.6s stimulus duration (Fig. 8C). There were no other differences between 4.5 months old 
3xTG females and age-matched controls during the first probe trial in premature 
responses (Figure 8D; RM-ANOVA, no effect of genotype, F(1,18) = 3.886, p = 0.0643;  
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Figure 8. Performance and response measures of 4.5 month-old 3xTG Females at 
the University of Western Ontario during the 5-CSRTT probe trials. Mice were 
subject to a series of probe trial schedules and the average values of the sessions are 
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D, 
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG females n=10, WT females n=10, data are mean ± SEM, *p<0.05, 
**p<0.01 and ****p<0.0001)  
Accuracy
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no effect of stimulus duration, F(3,54)  = 0.4987, p = 6848; no interaction effect, F(3,54) = 
0.4138, p = 0.7437) perseverative correct (Figure 8E; RM-ANOVA, no effect of 
genotype, F(1,18) = 1.127, p = 0.3025; main effect of stimulus duration, F(3,54)  = 4.963, p = 
0.0041; no interaction effect, F(3,54) = 1.330, p = 0.2742), or reward collection latency 
(Figure 8F; RM-ANOVA, no effect of genotype, F(1,18) = 2.551, p = 0.1276; no effect of 
stimulus duration, F(3,54)  = 2.590, p = 0.0622; no interaction effect, F(3,54) = 0.8387, p = 
0.4786).  
Seven month-old 3xTG females showed a significantly lower accuracy compared to age-
matched controls (Figure 9A; RM-ANOVA, main effect of genotype, F(1,17) = 10.48, p = 
0.0048; main effect of stimulus duration, F(3,51)  = 27.11, p < 0.0001; no interaction effect, 
F(3,51) = 1.860, p = 0.1481). In addition, they also had higher omissions (Figure 9B; RM-
ANOVA, main effect of genotype, F(1,17) = 4.890, p = 0.0410; main effect of stimulus 
duration, F(3,51)  = 19.63, p < 0.0001; no interaction effect, F(3,51) = 0.9319, p = 0.14321) 
and correct response latencies (Figure 9C; RM-ANOVA, main effect of genotype, F(1,17) 
= 10.35, p = 0.0051; no effect of stimulus duration, F(3,51)  = 0.4251, p = 0.7358; no 
interaction effect, F(3,51) = 0.3717, p = 0.7737). There were no differences between the 
genotypes in premature responses (Figure 9D; RM-ANOVA, no effect of genotype, 
F(1,17) = 0.3622, p = 0.5552; main effect of stimulus duration, F(3,51)  = 2.890, p = 0.0433; 
no interaction effect, F(3,51) = 0.7168, p = 0.5466), perseverative correct responses 
(Figure 9E; RM-ANOVA, no effect of genotype, F(1,17) = 6.392, p = 0.0517; main effect 
of stimulus duration, F(3,51)  = 4.773, p = 0.0052; no interaction effect, F(3,51) = 0.0653, p = 
0.978) or reward collection latencies (Figure 9F; RM-ANOVA, no effect of genotype,  
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Figure 9. Performance and response measures of 7 month-old 3xTG Females at 
the University of Western Ontario during the 5-CSRTT probe trials. Mice were 
subject to a series of probe trial schedules and the average values of the sessions are 
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D, 
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG females n=10, WT females n=9, data are mean ± SEM, *p<0.05 and 
**p<0.01)  
Accuracy
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F(1,17) = 0.0068, p = 0.9353; no effect of stimulus duration, F(3,51)  = 1.579, p = 0.2058; no 
interaction effect, F(3,51) = 1.118, p = 0.3506). 
Surprisingly, 10 month-old 3xTG females did not show a significant difference in 
accuracy when compared to controls (Figure 10A; RM-ANOVA, no effect of genotype, 
F(1,16) = 2.992, p = 0.1029; main effect of stimulus duration, F(3,48)  = 38.54, p < 0.0001; 
no interaction effect, F(3,48) = 0.7550, p = 0.5249), or omissions (Figure 10B; RM-
ANOVA, no effect of genotype, F(1,16) = 3.080, p = 0.0984; main effect of stimulus 
duration, F(3,48)  = 29.15, p < 0.0001; no interaction effect, F(3,48) = 1.189, p = 0.3237). 
The 3xTG females did show a higher correct response latency compared to controls 
(Figure 10C; RM-ANOVA, main effect of genotype, F(1,16) = 13.95, p = 0.0018; no effect 
of stimulus duration, F(3,48)  = 0.8806, p = 0.4578; no interaction effect, F(3,48) = 1.028, p = 
0.3885). However, no differences were observed between the 10 month-old genotypes in 
premature responses (Figure 10D; RM-ANOVA, no effect of genotype, F(1,16) = 0.8635, 
p = 0.3666; main effect of stimulus duration, F(3,48)  = 3.301, p = 0.0280; no interaction 
effect, F(3,48) = 0.5091, p = 0.6779), perseverative correct (Figure 10E; RM-ANOVA, no 
effect of genotype, F(1,16) = 3.542, p = 0.0817; main effect of stimulus duration, F(3,48)  = 
4.275, p = 0.0094; no interaction effect, F(3,48) = 1293, p = 0.2876), or reward collection 
latency (Figure 10F; RM-ANOVA, no effect of genotype, F(1,16) = 0.0590, p = 0.8111; 
main effect of stimulus duration, F(3,48)  = 1.208, p = 0.3170; no interaction effect, F(3,48) = 
1.118, p = 0.3510). 
 
  
  49 
 
Figure 10. Performance and response measures of 10 month-old 3xTG Females at 
the University of Western Ontario during the 5-CSRTT probe trials. Mice were 
subject to a series of probe trial schedules and the average values of the sessions are 
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D, 
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG females n=9, WT females n=9, data are mean ± SEM, **p<0.01)  
Accuracy
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3.4 Reproducibility of 3xTG Data Between Different Sites 
In order to test for reproducibility of data using the 5-CSRTT, age-matched 3xTG mice 
and controls were run at two separate sites, at the University of Western Ontario (site 1) 
and at the University of Guelph (site 2). Due to the potential for the greatest age-
dependent deficits related to AD-pathology, the accuracy data for the 10 month-old mice 
was analyzed to determine whether data obtained with touchscreens are indeed 
reproducible. For that we obtained data from Dr. Boyer Winters’ laboratory (Data 
obtained by the PhD student Daniel Palmer) who collaborates in this project. It should be 
noted that the results we obtained with 3xTG male mice in site 1 were already 
reproducing data previously published for these mice in touchscreens (Romberg et al 
2011). No difference was observed in performance of 10 month-old wild-type males 
between sites (Figure 11A; RM-ANOVA, no effect of genotype, F(1,15) = 1.153, p = 
0.2999; main effect of stimulus duration, F(3,45)  = 13.86, p < 0.0001; no interaction effect, 
F(3,45) = 0.3881, p = 0.7621) and no difference was observed in performance of 10 month-
old 3xTG males between sites (Figure 11B; RM-ANOVA, no effect of genotype, F(1,14) = 
2.362, p = 0.1466; main effect of stimulus duration, F(3,42)  = 28.68, p < 0.0001; no 
interaction effect, F(3,42) = 1.681, p = 0.1856). Similarly, we observed no difference 
between sites in performance of female wild-type mice (Figure 11C; RM-ANOVA, no 
effect of genotype, F(1,14) = 0.9362, p = 0.3497; main effect of stimulus duration, F(3,42)  = 
21.76, p < 0.0001; no interaction effect, F(3,42) = 0.2185, p = 0.8830), or the female 3xTG 
mice (Figure 11D; RM-ANOVA, no effect of genotype, F(1,17) = 1.614, p = 0.2210; main 
effect of stimulus duration, F(3,51)  = 41.20, p < 0.0001; no interaction effect, F(3,51) = 
0.3616, p = 0.7810). Despite some minor differences when we compared other  
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Figure 11. Comparison of the performance and response measures of 10 month-
old 3xTG and Wild-type Males and Females tested at the University of Western 
Ontario (London) and at the University of Guelph (Guelph) during the 5-CSRTT 
probe trials. Mice were subject to a series of probe trial schedules and the average 
values of the sessions are plotted. A, Mean accuracy for WT males. B, Mean accuracy 
for 3xTG males from both sites. C, Mean accuracy for WT females. D, Mean accuracy 
for 3xTG females. (Data are mean ± SEM). 
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parameters in all the ages, the results were mostly reproducible between sites (data not 
shown). Since there were no differences within groups of control and 3xTG mice, we 
analysed data between the two sites for all ages in order to increase statistical power and 
define robust age-dependent AD-related phenotypes in the 5-CSRTT touchscreen tests 
for this mouse line.  
Our analysis reveals that 3xTG male mice presented attention deficits when data were 
combined with decreased accuracy of 4.5 month-old mice (Figure 12A; RM-ANOVA, 
main effect of genotype, F(1,38) = 5.176, p = 0.0286; main effect of stimulus duration, 
F(3,114)  = 59.45, p < 0.0001; no interaction effect, F(3,114) = 0.8496, p = 0.4696), however 
we did not observe a difference in omissions (Figure 12B; RM-ANOVA, no effect of 
genotype, F(1,38) = 0.2818, p = 0.5986; main effect of stimulus duration, F(3,114)  = 61.76, p 
< 0.0001; no interaction effect, F(3,114) = 0.3983, p = 0.7545). The combined data also 
demonstrated a difference in correct response latency between genotypes (Figure 12C; 
RM-ANOVA, main effect of genotype, F(1,38) = 13.44, p = 0.0008; main effect of 
stimulus duration, F(3,114)  = 10.70, p < 0.0001; no interaction effect, F(3,114) = 0.4505, p = 
0.7174). No differences were observed between the combined 4.5 month-old 3xTG males 
and controls in premature responses (Figure 12D; RM-ANOVA, no effect of genotype, 
F(1,38) = 0.1597, p = 0.6917; main effect of stimulus duration, F(3,114)  = 3.496, p = 0.0186; 
no interaction effect, F(3,114) = 0.0727, p = 0.9745), perseverative correct (Figure 12E; 
RM-ANOVA, no effect of genotype, F(1,38) = 1.989, p = 0.1666; main effect of stimulus 
duration, F(3,114)  = 9.698, p < 0.0001; no interaction effect, F(3,114) = 1.845, p = 0.1430), 
or reward collection latency (Figure 12F; RM-ANOVA, no effect of genotype, F(1,38) =  
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Figure 12. Performance and response measures of the combined data for 4.5 
month-old 3xTG Males at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG males n=22, WT males n=19, data are mean ± SEM, *p<0.05 and 
***p<0.001)  
Accuracy
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1.899, p = 0.1762; no effect of stimulus duration, F(3,114)  = 1.049, p = 0.3740; no 
interaction effect, F(3,114) = 0.3240, p = 0.8080). 
Combined data obtained with 7 month-old 3xTG and control male mice showed both a 
genotype and interaction difference in accuracy (Figure 13A; RM-ANOVA, main effect 
of genotype, F(1,31) = 7.876, p = 0.0086; main effect of stimulus duration, F(3,93)  = 48.29, p 
< 0.0001; main interaction effect, F(3,93) = 3.546, p = 0.0175) and a Post-hoc analysis 
revealed a significant difference between at the 0.6s stimulus duration (Fig. 13A). There 
were no differences observed for omissions (Figure 13B; RM-ANOVA, no effect of 
genotype, F(1,31) = 0.9227, p = 0.3442; main effect of stimulus duration, F(3,93)  = 59.83, p 
< 0.0001; no interaction effect, F(3,93) = 0.0046, p = 0.9996). The combined data 
demonstrated that 7 month-old 3xTG males continued to have higher correct response 
latencies compared to age-matched controls (Figure 13C; RM-ANOVA, main effect of 
genotype, F(1,31) = 14.80, p = 0.0006; main effect of stimulus duration, F(3,93)  = 10.44, p < 
0.0001; no interaction effect, F(3,93) = 1.077, p = 0.3692). No difference in performance 
was observed in premature responses (Figure 13D; RM-ANOVA, no effect of genotype, 
F(1,31) = 4802, p = 0.4935; main effect of stimulus duration, F(3,93)  = 3.449, p = 0.0198; no 
interaction effect, F(3,93) = 0.6072, p = 0.6120), number of perseverative correct responses 
(Figure 13E; RM-ANOVA, no effect of genotype, F(1,31) = 0.0082, p = 0.9285; main 
effect of stimulus duration, F(3,93)  = 5.594, p = 0014; no interaction effect, F(3,93) = 
0.8452, p = 0.4726), or reward collection latency (Figure 13F; RM-ANOVA, no effect 
of genotype, F(1,31) = 0.2646, p = 0.6107; no effect of stimulus duration, F(3,93)  = 1.553, p 
= 0.2060; no interaction effect, F(3,93) = 1.904, p = 0.0889).  
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Figure 13. Performance and response measures of the combined data for 7 
month-old 3xTG Males at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG males n=18, WT males n=15, data are mean ± SEM, **p<0.01 and 
***p<0.001)  
Accuracy
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At 10 months of age, the combined data demonstrated that male 3xTG mice continued to 
display both a genotype and interaction difference in accuracy (Figure 14A; RM-
ANOVA, main effect of genotype, F(1,31) = 5.459, p = 0.0261; main effect of stimulus 
duration, F(3,93)  = 43.61, p < 0.0001; main interaction effect, F(3,93) = 5.000, p = 0.0029). 
A post-hoc analysis revealed a difference between genotypes at the 0.6s stimulus duration 
(Fig. 14A). The data from both sites also revealed a difference in omissions when we 
compared the male mice from the two genotypes (Figure 14B; RM-ANOVA, main effect 
of genotype, F(1,31) = 4.610, p = 0.0397; main effect of stimulus duration, F(3,93)  = 43.38, p 
< 0.0001; no interaction effect, F(3,93) = 1.794, p = 0.1538). Likewise, the transgenic 
males continued to demonstrate increased correct response latency compared to controls 
(Figure 14C; RM-ANOVA, main effect of genotype, F(1,31) = 7.398, p = 0.0106; no effect 
of stimulus duration, F(3,93)  = 0.4928, p = 0.6882; no interaction effect, F(3,93) = 0.6931, p 
= 0.5585). However, no differences in premature responses (Figure 14D; RM-ANOVA, 
no effect of genotype, F(1,31) = 0.0664, p = 0.7983; no effect of stimulus duration, F(3,93)  = 
1.613, p = 0.1917; no interaction effect, F(3,93) = 0.2399, p = 0.8683), perseverative 
correct (Figure 14E; RM-ANOVA, no effect of genotype, F(1,31) = 0.3807, p = 0.5417; 
main effect of stimulus duration, F(3,93)  = 3.643, p = 0.0194; no interaction effect, F(3,93) = 
.4961, p = 0.6859) or reward collection latency (Figure 14F; RM-ANOVA, no effect of 
genotype, F(1,31) = 0.2939, p = 0.5916; no effect of stimulus duration, F(3,93)  = 2.573, p = 
0.0587; no interaction effect, F(3,93) = 0.4875, p = 0.6918) were observed in the data from 
both sites.  
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Figure 14. Performance and response measures of the combined data for 10 
month-old 3xTG Males at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG males n=16, WT males n=17, data are mean ± SEM, *p<0.05 and 
***p<0.001)  
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The combination of data between sites also revealed the 3xTG females to have a 
significantly lower accuracy during the 4.5 month-old probes (Figure 15A; RM-
ANOVA, main effect of genotype, F(1,35) = 6.358, p = 0.0164; main effect of stimulus 
duration, F(3,105)  = 48.35, p < 0.0001; no interaction effect, F(3,105) = 0.8023, p = 0.4953), 
but no difference in omissions (Figure 15B; RM-ANOVA, no effect of genotype, F(1,35) = 
1.623, p = 0.2111; main effect of stimulus duration, F(3,105)  = 94.38, p < 0.0001; no 
interaction effect, F(3,105) = 0.9048, p = 0.4415). In addition, female 3xTG mice showed 
an increase in correct response latency (Figure 15C; RM-ANOVA, main effect of 
genotype, F(1,35) = 16.26, p = 0.0003; main effect of stimulus duration, F(3,105)  = 3.911, p 
= 0.0108; no interaction effect, F(3,105) = 1.111, p = 0.3480), and decreased premature 
responses (Figure 15D; RM-ANOVA, main effect of genotype, F(1,35) = 5.465, p = 
0.0252; no effect of stimulus duration, F(3,105)  = 0.8707, p = 0.4588; no interaction effect, 
F(3,105) = 0.1364, p = 0.9381). The combined data for the 4.5 month-old 3xTG females 
and controls did not reveal a difference in perseverative correct responses (Figure 15E; 
RM-ANOVA, no effect of genotype, F(1,35) = 1.563, p = 0.2195; main effect of stimulus 
duration, F(3,105)  = 8.066, p < 0.0001; no interaction effect, F(3,105) = 0.6851, p = 0.5631), 
or reward collection latency (Figure 15F; RM-ANOVA, no effect of genotype, F(1,35) = 
0.1229, p = 0.7280; no effect of stimulus duration, F(3,105)  = 1.947, p = 0.1266; no 
interaction effect, F(3,105) = 0.8414, p = 0.4742).  
Combined data between sites for probe trials at 7 months of age showed 3xTG females to 
have deficits in accuracy compared to controls (Figure 16A; RM-ANOVA, main effect 
of genotype, F(1,32) = 6.825, p = 0.0136; main effect of stimulus duration, F(3,96)  = 52.40, p 
< 0.0001; no interaction effect, F(3,96) = 0.8580, p = 0.4657). Interestingly, the combined  
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WT Females   n=17 3xTG Females   n=20
Figure 15. Performance and response measures of the combined data for 4.5 
month-old 3xTG Females at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG females n=20, WT females n=17, data are mean ± SEM, *p<0.05 and 
***p<0.001)  
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WT Females   n=15 3xTG Females   n=20
Figure 16. Performance and response measures of the combined data for 7 
month-old 3xTG Females at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG females n=20, WT females n=15, data are mean ± SEM, *p<0.05 and 
**p<0.01)  
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data revealed that the 3xTG females had deficits in omissions compared to controls 
(Figure 16B; RM-ANOVA, main effect of genotype, F(1,32) = 4.552, p = 0.0406; main 
effect of stimulus duration, F(3,96)  = 43.13, p < 0.0001; no interaction effect, F(3,96) = 
1.413, p = 0.2437). Differences were also observed between genotypes in correct 
response latency (Figure 16C; RM-ANOVA, main effect of genotype, F(1,32) = 10.87, p = 
0.0024; main effect of stimulus duration, F(3,96)  = 2.868, p = 0.0405; no interaction effect, 
F(3,96) = 0.1061, p = 0.9563). The combined data revealed no differences between females 
3xTG and control mice in premature responses (Figure 16D; RM-ANOVA, no effect of 
genotype, F(1,32) = 0.0202, p = 0.8880; main effect of stimulus duration, F(3,96)  = 4.567, p 
= 0.0049; no interaction effect, F(3,96) = 0.3085, p = 0.8192), perseverative correct 
(Figure 16E; RM-ANOVA, no effect of genotype, F(1,32) = 4.868, p = 0.0547; main effect 
of stimulus duration, F(3,96)  = 7.045, p = 0.0002; no interaction effect, F(3,96) = 0.0609, p = 
0.9802), or reward collection latency (Figure 16F; RM-ANOVA, no effect of genotype, 
F(1,32) = 0.3668, p = 0.5490; no effect of stimulus duration, F(3,96)  = 2.188, p = 0.0945; no 
interaction effect, F(3,96) = 1.831, p = 0.1467).  
At 10 months of age, combined data revealed female 3xTG mice to have significantly 
decreased accuracy compared to controls (Figure 17A; RM-ANOVA, main effect of 
genotype, F(1,33) = 5.324, p = 0.0275; main effect of stimulus duration, F(3,99)  = 63.86, p < 
0.0001; no interaction effect, F(3,99) = 1.069, p = 0.3659).  However, no difference was 
observed in omissions (Figure 17B; RM-ANOVA, no effect of genotype, F(1,33) = 0.0313, 
p = 0.8606; main effect of stimulus duration, F(3,99)  = 52.14, p < 0.0001; no interaction 
effect, F(3,99) = 1.039, p = 0.3788). The combined data also demonstrated that transgenic 
females have an increased correct response latency compared to age-matched controls 
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(Figure 17C; RM-ANOVA, main effect of genotype, F(1,33) = 9.202, p = 0.0047; main 
effect of stimulus duration, F(3,99)  = 4.156, p = 0.0081; no interaction effect, F(3,99) = 
0.9700, p = 0.4101). The 10 month-old females did not display any differences in 
premature responses (Figure 17D; RM-ANOVA, no effect of genotype, F(1,33) = 0.0873, 
p = 0.7695; no effect of stimulus duration, F(3,99)  = 1.883, p = 0.1374; no interaction 
effect, F(3,99) = 0.1473, p = 0.9312), perseverative correct, although there was a tendency 
for the transgenic mice to have lower responses compared to controls, (Figure 17E; RM-
ANOVA, no effect of genotype, F(1,33) = 3.663, p = 0.0643; main effect of stimulus 
duration, F(3,99)  = 8.001, p < 0.0001; no interaction effect, F(3,99) = 2.262, p = 0.0860), or 
reward collection latency (Figure 17F; RM-ANOVA, no effect of genotype, F(1,33) = 
1.385, p = 0.2477; no effect of stimulus duration, F(3,99)  = 0.4324, p = 0.7303; no 
interaction effect, F(3,99) = 1.078, p = 0.3621). 
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WT Females   n=16 3xTG Females   n=19
Figure 17. Performance and response measures of the combined data for 10 
month-old 3xTG Females at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (3xTG females n=19, WT females n=16, data are mean ± SEM, *p<0.05 and 
**p<0.01)  
  64 
3.5 Attention Capacity of Male 5xFAD mice 
Several AD mouse lines have been generated presenting distinct deficits at different ages 
(Webster et al., 2014). Whether distinct AD mice may present similar phenotypes that 
could be predictable for future interventions needs to be clarified. We therefore obtained 
data for attentional performance in a second AD mouse line which presents fast 
developing amyloidosis due to combined mutations in APP and PSEN1, the 5xFAD line 
(Oakley et al., 2006). We chose to test this mouse line longitudinally at 4.5, 7 and 10 
months of age on the 5-CSRTT based on data from previous experiments that have 
shown the progression of AD-like pathology (Oakley et al., 2006). In addition, testing at 
the same ages as the 3xTG mice allowed us to determine to what extent there were any 
age-dependent differences between the mouse lines.  
The 4.5 month-old 5xFAD male mice did not show any difference in accuracy compared 
to controls during the first probe trials (Figure 18A; RM-ANOVA, no effect of genotype, 
F(1,19) = 0.2634, p = 0.6137; main effect of stimulus duration, F(3,57)  = 27.06, p < 0.0001; 
no interaction effect, F(3,57) = 0.8136, p = 0.4917). In addition, performance did not differ 
between the 5xFAD males and controls in omissions (Figure 18B; RM-ANOVA, no 
effect of genotype, F(1,19) = 0.4977, p = 0.4891; main effect of stimulus duration, F(3,57)  = 
54.79, p < 0.0001; no interaction effect, F(3,57) = 0.5362, p = 0.6594), correct response 
latency (Figure 18C; RM-ANOVA, no effect of genotype, F(1,19) = 3.832, p = 0.0651; no 
effect of stimulus duration, F(3,57)  = 2.645, p = 0.0577; no interaction effect, F(3,57) = 
0.1085, p = 0.9548), premature responses (Figure 18D; RM-ANOVA, no effect of 
genotype, F(1,19) = 0.0606, p = 0.8082; main effect of stimulus duration, F(3,57)  = 2.918, p 
= 0.0481; no interaction effect, F(3,57) = 6.003, p = 0.0013), perseverative correct  
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Figure 18. Performance and response measures for 4.5 month-old 5xFAD Males 
at the University of Western Ontario during the 5-CSRTT probe trials. Mice 
were subject to a series of probe trial schedules and the average values of the sessions 
are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. 
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward 
collection latency (5xFAD males n=12, WT males n=12, data are mean ± SEM) 
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responses (Figure 18E; RM-ANOVA, no effect of genotype, F(1,19) = 1.749, p = 0.2017; 
main effect of stimulus duration, F(3,57)  = 3.097, p = 0.0339; no interaction effect, F(3,57) = 
0.7475, p = 0.5283), or reward collection latency (Figure 18F; RM-ANOVA, no effect 
of genotype, F(1,19) = 0.0077, p = 0.9310; no effect of stimulus duration, F(3,57)  = 0.1122, p 
= 0.9527; no interaction effect, F(3,57) = 0.05497, p = 0.6504). 
Similarly, at 7 months, performance of 5xFAD males did not differ from that of controls 
in accuracy (Figure 19A; RM-ANOVA, no effect of genotype, F(1,21) = 2.403, p = 
0.1360; main effect of stimulus duration, F(3,63)  = 28.34, p < 0.0001; main interaction 
effect, F(3,63) = 3.157, p = 0.0308), or omissions (Figure 19B; RM-ANOVA, no effect of 
genotype, F(1,21) = 0.6592, p = 0.4260; main effect of stimulus duration, F(3,63)  = 29.56, p 
< 0.0001; no interaction effect, F(3,63) = 1.304, p = 0.2811). Although no significant 
differences were observed between genotypes in correct response latency (Figure 19C; 
RM-ANOVA, no effect of genotype, F(1,21) = 4.807, p = 0.0562; no effect of stimulus 
duration, F(3,63)  = 1.333, p = 0.2718; no interaction effect, F(3,63) = 0.3872, p = 0.7626), 
there is a strong tendency for 5xFAD males to take longer to respond.  In addition, no 
differences were observed between genotypes in premature responses (Figure 19D; RM-
ANOVA, no effect of genotype, F(1,21) = 0.0034, p = 0.9544; no effect of stimulus 
duration, F(3,63)  = 2.260, p = 0.0901; no interaction effect, F(3,63) = 2.823, p = 0.0558), or 
perseverative correct (Figure 19E; RM-ANOVA, no effect of genotype, F(1,21) = 2.492, p 
= 0.1293; main effect of stimulus duration, F(3,63)  = 3.090, p = 0.0333; no interaction 
effect, F(3,63) = 0.9327, p = 0.4302). The male 5xFAD mice did have higher reward 
collection latencies compared to controls (Figure 19F; RM-ANOVA, main effect of  
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Figure 19. Performance and response measures for 7 month-old 5xFAD Males at 
the University of Western Ontario during the 5-CSRTT probe trials. Mice were 
subject to a series of probe trial schedules and the average values of the sessions are 
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D, 
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (5xFAD males n=12, WT males n=11, data are mean ± SEM) 
  68 
genotype, F(1,21) = 4.671, p = 0.0424; no effect of stimulus duration, F(3,63)  = 1.290, p = 
0.2856; no interaction effect, F(3,63) = 0.4530, p = 0.7161).  
Interestingly, at 10 months of age, 5xFAD male mice revealed decreased accuracy, the 
main measure of attention in the 5-CSRTT, with both a genotype and interaction 
difference (Figure 20A; RM-ANOVA, main effect of genotype, F(1,22) = 5.824, p = 
0.0293; main effect of stimulus duration, F(3,66)  = 54.53, p < 0.0001; main interaction 
effect, F(3,66) = 2.879, p = 0.0425). Post-hoc analysis demonstrated significant differences 
at both the 0.8s and 0.6s stimulus duration between genotypes (Fig. 20A). No differences 
in omission were observed between transgenic and wild-type males (Figure 20B; RM-
ANOVA, no effect of genotype, F(1,22) = 3.030, p = 0.0957; main effect of stimulus 
duration, F(3,66)  = 24.59, p < 0.0001; no interaction effect, F(3,66) = 1.165, p = 0.3296). In 
addition, 10 month-old 5xFAD males had a significantly higher correct response latency 
compared to age-matched controls (Figure 20C; RM-ANOVA, main effect of genotype, 
F(1,22) = 15.38, p = 0.0007; main effect of stimulus duration, F(3,66)  = 23.87, p < 0.0001; 
no interaction effect, F(3,66) = 1.618, p = 0.1936), but showed no difference in premature 
responses (Figure 20D; RM-ANOVA, no effect of genotype, F(1,22) = 0.4828, p = 0.4944; 
main effect of stimulus duration, F(3,66)  = 4.437, p = 0.0067; no interaction effect, F(3,66) = 
1.282, p = 0.2879). In contrast, 5xFAD males demonstrated a difference from control 
mice in both perseverative correct responses (Figure 20E; RM-ANOVA, main effect of 
genotype, F(1,22) = 11.66, p = 0.0025; main effect of stimulus duration, F(3,66)  = 10.18, p < 
0.0001; no interaction effect, F(3,66) = 2.223, p = 0.0937), and reward collection latency 
(Figure 20F; RM-ANOVA, main effect of genotype, F(1,22) = 34.34, p < 0.0001; no effect  
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Figure 20. Performance and response measures for 10 month-old 5xFAD Males 
at the University of Western Ontario during the 5-CSRTT probe trials. Mice 
were subject to a series of probe trial schedules and the average values of the sessions 
are plotted.  A, Mean accuracy. B, Mean omission. C, Mean correct response latency. 
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward 
collection latency (5xFAD males n=12, WT males n=12, data are mean ± SEM, 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001) 
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of stimulus duration, F(3,66)  = 1.617, p = 0.1937; no interaction effect, F(3,66) = 1.954, p = 
0.1294) compared to controls.  
 
3.6 Performance of 5xFAD Female Mice 
We also investigated whether 5xFAD female mice display any deficits in the 5-CSRTT 
compared to controls. 4.5 month-old 5xFAD females did not show a difference in 
accuracy compared to wild-type controls (Figure 21A; RM-ANOVA, no effect of 
genotype, F(1,21) = 0.3098, p = 0.5837; main effect of stimulus duration, F(3,63)  = 36.61, p 
< 0.0001; no interaction effect, F(3,63) = 1.187, p = 0.3221). Likewise, no difference was 
observed between the genotypes in omissions (Figure 21B; RM-ANOVA, no effect of 
genotype, F(1,21) = 0.0742, p = 0.7880; main effect of stimulus duration, F(3,63)  = 42.37, p 
< 0.0001; no interaction effect, F(3,63) = 2.264, p = 0.0897), correct response latency 
(Figure 21C; RM-ANOVA, no effect of genotype, F(1,21) = 0.7868, p = 0.3851; main 
effect of stimulus duration, F(3,63)  = 12.57, p < 0.0001; no interaction effect, F(3,63) = 
0.7074, p = 0.5512), premature responses (Figure 21D; RM-ANOVA, no effect of 
genotype, F(1,21) = 0.0122, p = 0.9131; main effect of stimulus duration, F(3,63)  = 4.332, p 
= 0.0077; no interaction effect, F(3,63) = 0.01206, p = 0.9476), perseverative correct 
(Figure 21E; RM-ANOVA, no effect of genotype, F(1,21) = 2.605, p = 0.1214; main effect 
of stimulus duration, F(3,63)  = 3.665, p = 0.0168; no interaction effect, F(3,63) = 0.1445, p = 
0.9328), or reward collection latency (Figure 21F; RM-ANOVA, no effect of genotype, 
F(1,21) = 0.0005, p = 0.9819; no effect of stimulus duration, F(3,63)  = 1.700, p = 0.1760; no 
interaction effect, F(3,63) = 0.1528, p = 0.9275).  
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WT Females   n=11 5xFAD Females   n=12
Figure 21. Performance and response measures for 4.5 month-old 5xFAD 
Females at the University of Western Ontario during the 5-CSRTT probe trials. 
Mice were subject to a series of probe trial schedules and the average values of the 
sessions are plotted.  A, Mean accuracy. B, Mean omission. C, Mean correct response 
latency. D, Mean premature responses. E, Mean perseverative correct. F, Mean reward 
collection latency (5xFAD females n=12, WT females n=11, data are mean ± SEM) 
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The 7 month-old female 5xFAD mice did not reveal a difference in accuracy, albeit there 
was a tendency for worse performance by the transgenic mice (Figure 22A; RM-
ANOVA, no effect of genotype, F(1,17) = 3.081, p = 0.0972; main effect of stimulus 
duration, F(3,51)  = 28.75, p < 0.0001; no interaction effect, F(3,51) = 1.407, p = 0.2513) or 
omissions (Figure 22B; RM-ANOVA, no effect of genotype, F(1,17) = 1.937, p = 0.1819; 
main effect of stimulus duration, F(3,51)  = 20.93, p < 0.0001; no interaction effect, F(3,51) = 
0.9139, p = 0.4408). However, 5xFAD females did display an increased correct response 
latency compared to controls (Figure 22C; RM-ANOVA, main effect of genotype, F(1,17) 
= 11.37, p = 0.0036; no effect of stimulus duration, F(3,51) = 1.248, p = 0.3021; no 
interaction effect, F(3,51) = 1.788, p = 0.1611), but no difference was observed in 
premature responses (Figure 22D; RM-ANOVA, no effect of genotype, F(1,17) = 0.5379, 
p = 0.4733; no effect of stimulus duration, F(3,51)  = 1.705, p = 0.1776; no interaction 
effect, F(3,51) = 0.5160, p = 0.6732). A difference was observed between genotypes for 
perseverative correct (Figure 22E; RM-ANOVA, main effect of genotype, F(1,17) = 6.266, 
p = 0.0228; no effect of stimulus duration, F(3,51)  = 2.183, p = 0.1014; no interaction 
effect, F(3,51) = 0.5370, p = 0.6590), as well as reward collection latency (Figure 22F; 
RM-ANOVA, main effect of genotype, F(1,17) = 5.645, p = 0.0295; main effect of 
stimulus duration, F(3,51)  = 3.886, p = 0.0141; no interaction effect, F(3,51) = 0.9660, p = 
0.4160).  
At 10 months of age, female 5xFAD mice showed a significant decrease in accuracy 
compared to controls (Figure 23A; RM-ANOVA, main effect of genotype, F(1,14) = 
5.434, p = 0.0352; main effect of stimulus duration, F(3,42)  = 23.85, p < 0.0001; no 
interaction effect, F(3,42) = 1.530, p = 0.2208). However, no difference was observed  
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WT Females   n=9 5xFAD Females   n=10
Figure 22. Performance and response measures for 7 month-old 5xFAD Females 
at the University of Western Ontario during the 5-CSRTT probe trials. Mice 
were subject to a series of probe trial schedules and the average values of the sessions 
are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. 
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward 
collection latency (5xFAD females n=10, WT females n=9, data are mean ± SEM, 
*p<0.05 and **p<0.01) 
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WT Females   n=7 5xFAD Females   n=9
Figure 23. Performance and response measures for 10 month-old 5xFAD Females 
at the University of Western Ontario during the 5-CSRTT probe trials. Mice 
were subject to a series of probe trial schedules and the average values of the sessions 
are plotted.A, Mean accuracy. B, Mean omission. C, Mean correct response latency. 
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward 
collection latency (5xFAD females n=9, WT females n=7, data are mean ± SEM) 
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between genotypes in omissions (Figure 23B; RM-ANOVA, no effect of genotype, F(1,14) 
= 1.987, p = 0.1805; main effect of stimulus duration, F(3,42)  = 29.56, p < 0.0001; no 
interaction effect, F(3,42) = 1.465, p = 0.2379), correct response latency (Figure 23C; RM-
ANOVA, no effect of genotype, F(1,14) = 1.639, p = 0.2213; main effect of stimulus 
duration, F(3,42)  = 6.632, p = 0.0009; no interaction effect, F(3,42) = 0.8247, p = 0.4877), 
premature responses (Figure 23D; RM-ANOVA, no effect of genotype, F(1,14) = 0.6063, 
p = 0.4492; no effect of stimulus duration, F(3,42)  = 0.9553, p = 0.4227; no interaction 
effect, F(3,42) = 0.2637, p = 0.8512), perseverative correct responses (Figure 23E; RM-
ANOVA, no effect of genotype, F(1,14) = 2.369, p = 0.1461; no effect of stimulus duration, 
F(3,42)  = 1.194, p = 0.3238; no interaction effect, F(3,42) = 0.0909, p = 0.9646), or reward 
collection latency (Figure 23F; RM-ANOVA, no effect of genotype, F(1,14) = 1.875, p = 
0.1925; no effect of stimulus duration, F(3,42)  = 2257, p = 0.8780; no interaction effect, 
F(3,42) = 0.6030, p = 0.6167). 
 
3.7 Reproducibility of 5xFAD Data Between Sites 
The 5xFAD mouse line was also run simultaneously at site 1 and site 2 in order to 
determine whether the 5-CSRTT data are reproducible. Again, accuracy from the 10 
month-old mice was analysed because this is where we observed the largest difference 
between genotypes. Male wild-type mice displayed no difference in accuracy between 
sites (Figure 24A; RM-ANOVA, no effect of genotype, F(1,20) = 1.191, p = 0.2881; main 
effect of stimulus duration, F(3,60)  = 36.22, p < 0.0001; no interaction effect, F(3,60) = 
0.2995, p = 0.8256), nor did the 5xFAD mice (Figure 24B; RM-ANOVA, no effect of 
genotype, F(1,21) = 1.133, p = 0.2992; main effect of stimulus duration, F(3,63)  = 77.10, p <  
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Figure 24. Comparison of the performance and response measures of 10 month-
old 5xFAD and Wild-type Males and Females tested at the University of Western 
Ontario (London) and at the University of Guelph (Guelph) during the 5-CSRTT 
probe trials. Mice were subject to a series of probe trial schedules and the average 
values of the sessions are plotted. A, Mean accuracy for WT males. B, Mean accuracy 
for 5xFAD males from both sites. C, Mean accuracy for WT females. D, Mean 
accuracy for 5xFAD females. (Data are mean ± SEM). 
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0.0001; no interaction effect, F(3,63) = 0.7266, p = 0.5399). Likewise, 10 month-old wild-
type females did not exhibit a difference in accuracy when compared between the two 
sites (Figure 24C; RM-ANOVA, no effect of genotype, F(1,13) = 0.8213, p = 0.3785; main 
effect of stimulus duration, F(3,39)  = 57.62, p < 0.0001; no interaction effect, F(3,39) = 
1.216, p = 0.3169). There was also no difference observed in the performance of the two 
groups of 5xFAD females between sites (Figure 24D; RM-ANOVA, no effect of 
genotype, F(1,17) = 1.826, p = 0.1943; main effect of stimulus duration, F(3,51)  = 19.82, p < 
0.0001; no interaction effect, F(3,51) = 1.546, p = 0.2094). The comparison of data for 
many of the other relevant parameters also revealed very little differences between sites 
(not shown). This suggests that data for the 5xFAD mouse line are also reproducible 
between sites 1 and 2. We obtained data from Dr. Winters’ group and combined the 
analysis to increase statistical power and define the most robust phenotypes.  
Attention capacity of male 5xFAD mice (combining the data from both sites) was 
analyzed. There was no difference in accuracy between 4.5 month-old 5xFAD males and 
controls (Figure 25A; RM-ANOVA, no effect of genotype, F(1,37) = 0.0001, p = 0.9968; 
main effect of stimulus duration, F(3,111)  = 43.46, p < 0.0001; no interaction effect, F(3,111) 
= 0.5811, p = 0.6286). In addition, no difference in genotypes were observed in 
omissions (Figure 25B; RM-ANOVA, no effect of genotype, F(1,37) = 0.3821, p = 0.5403; 
main effect of stimulus duration, F(3,111)  = 81.32, p < 0.0001; no interaction effect, F(3,111) 
= 1.268, p = 0.2889), correct response latency (Figure 25C; RM-ANOVA, no effect of 
genotype, F(1,37) = 2.576, p = 0.1170; main effect of stimulus duration, F(3,111)  = 4.981, p 
= 0.0028; no interaction effect, F(3,111) = 0.3271, p = 0.8058), premature responses 
(Figure 25D; RM-ANOVA, no effect of genotype, F(1,37) = 0.1064, p = 0.7461; main  
  78 
 
Accuracy






















































































































Figure 25. Performance and response measures of the combined data for 4.5 
month-old 5xFAD Males at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (5xFAD males n=19, WT males n=20, data are mean ± SEM) 
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effect of stimulus duration, F(3,111)  = 3.400, p = 0.0203; no interaction effect, F(3,111) = 
2.403, p = 0.0714), perseverative correct responses (Figure 25E; RM-ANOVA, no effect 
of genotype, F(1,37) = 0.3285, p = 0.5700; main effect of stimulus duration, F(3,111)  = 
7.363, p = 0.0002; no interaction effect, F(3,111) = 0.5485, p = 0.6502), or reward 
collection latency (Figure 25F; RM-ANOVA, no effect of genotype, F(1,37) = 0.2046, p = 
0.6537; main effect of stimulus duration, F(3,111)  = 0.4887, p = 0.6908; no interaction 
effect, F(3,111) = 0.5517, p = 0.6480).  
At 7 months, 5xFAD males from the combined data displayed a significant difference in 
accuracy compared to age-matched controls (Figure 26A; RM-ANOVA, main effect of 
genotype, F(1,43) = 0.5.658, p = 0.0219; main effect of stimulus duration, F(3,129)  = 63.72, p 
< 0.0001; no interaction effect, F(3,129) = 0.4193, p = 0.7394) but had no significant 
change in omissions (Figure 26B; RM-ANOVA, no effect of genotype, F(1,43) = 1.862, p 
= 0.1794; main effect of stimulus duration, F(3,129)  = 61.63, p < 0.0001; no interaction 
effect, F(3,129) = 0.4579, p = 0.7122). Combined data at 7 months did show male 5xFAD 
mice to have significant difference in correct response latency compared to controls 
(Figure 26C; RM-ANOVA, main effect of genotype, F(1,43) = 9.435, p = 0.0037; main 
effect of stimulus duration, F(3,129)  = 5.898, p = 0.0008; no interaction effect, F(3,129) = 
0.3240, p = 0.8080).  No difference between genotypes was observed in premature 
responses (Figure 26D; RM-ANOVA, no effect of genotype, F(1,43) = 0.4497, p = 0.5061; 
main effect of stimulus duration, F(3,129)  = 2.875, p = 0.0388; no interaction effect, F(3,129) 
= 0.7579, p = 0.5197). Also, combined data for 7 month-old 5xFAD males displayed a 
difference compared to controls in perseverative correct responses (Figure 26E; RM-
ANOVA, main effect of genotype, F(1,43) = 10.54, p = 0.0023; main effect of stimulus  
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Figure 26. Performance and response measures of the combined data for 7 
month-old 5xFAD Males at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (5xFAD males n=24, WT males n=21, data are mean ± SEM, *p<0.05 and 
**p<0.01) 
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duration, F(3,129)  = 9.837, p < 0.0001; no interaction effect, F(3,129) = 2.265, p = 0.0841), 
and decreased reward collection latency (Figure 26F; RM-ANOVA, main effect of 
genotype, F(1,43) = 6.657, p = 0.0134; no effect of stimulus duration, F(3,129)  = 1.354, p = 
0.2599; no interaction effect, F(3,129) = 0.5902, p = 0.6255).  
The combined data for 10 month-old 5xFAD males demonstrated increased deficits in 
accuracy with both a genotype and interaction difference (Figure 27A; RM-ANOVA, 
main effect of genotype, F(1,43) = 8.148, p = 0.0066; main effect of stimulus duration, 
F(3,129)  = 111.4, p < 0.0001; main interaction effect, F(3,129) = 3.474, p = 0.0181) and the  
post-hoc analysis revealed a significantly lower accuracy at both the 0.8s and 0.6s 
stimulus durations for the transgenic males compared to controls (Fig. 27A). In addition, 
significant differences were observed between genotypes in omissions (Figure 27B; RM-
ANOVA, main effect of genotype, F(1,43) = 7.570, p = 0.0087; main effect of stimulus 
duration, F(3,129)  = 50.52, p < 0.0001; no interaction effect, F(3,129) = 1.358, p = 0.2586), 
and correct response latency (Figure 27C; RM-ANOVA, main effect of genotype, F(1,43) 
= 21.20, p < 0.0001; main effect of stimulus duration, F(3,129)  = 22.78, p < 0.0001; main 
interaction effect, F(3,129) = 31.67, p = 0.0267). The 10 month-old male 5xFAD mice did 
not show a difference in premature responses compared to controls in the combined data 
(Figure 27D; RM-ANOVA, no effect of genotype, F(1,43) = 0.0244, p = 0.8765; main 
effect of stimulus duration, F(3,129)  = 6.549, p = 0.0004; no interaction effect, F(3,129) = 
1.538, p = 0.2078). However, compared to age-matched controls, the performance of 
5xFAD males did differ for perseverative correct (Figure 27E; RM-ANOVA, main effect 
of genotype, F(1,43) = 11.19, p = 0.0017; main effect of stimulus duration, F(3,129)  = 11.93, 
p < 0.0001; no interaction effect, F(3,129) = 0.3469, p = 0.7914), and reward collection  
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Figure 27. Performance and response measures of the combined data for 10 
month-old 5xFAD Males at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (5xFAD males n=23, WT males n=22, data are mean ± SEM, **p<0.01 and 
****p<0.0001) 
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latency (Figure 27F; RM-ANOVA, main effect of genotype, F(1,43) = 8.621, p = 0.0053; 
no effect of stimulus duration, F(3,129)  = 1.237, p = 0.2989; no interaction effect, F(3,129) = 
1.418, p = 0.2405).  
The performance of the 5xFAD females (combined data from both sites) was analyzed 
and revealed no differences in accuracy between the transgenic and wild-type controls at 
4.5 months of age (Figure 28A; RM-ANOVA, no effect of genotype, F(1,42) = 0.5529, p = 
0.4613; main effect of stimulus duration, F(3,126)  = 44.61, p < 0.0001; no interaction 
effect, F(3,126) = 0.8749, p = 0.4561). Similarly, no differences was observed between 
genotypes in omissions (Figure 28B; RM-ANOVA, no effect of genotype, F(1,42) = 
0.0902, p = 0.7654; main effect of stimulus duration, F(3,126)  = 41.99, p < 0.0001; no 
interaction effect, F(3,126) = 1.410, p = 0.2429), correct response latency (Figure 28C; 
RM-ANOVA, no effect of genotype, F(1,42) = 0.4515, p = 0.5053; main effect of stimulus 
duration, F(3,126)  = 8.164, p < 0.0001; no interaction effect, F(3,126) = 0.6658, p = 0.5746), 
premature responses (Figure 28D; ; RM-ANOVA, no effect of genotype, F(1,42) = 0.4112, 
p = 0.5248; no effect of stimulus duration, F(3,126)  = 1.906, p = 0.1320; no interaction 
effect, F(3,126) = 0.4807, p = 0.6963), perseverative correct (Figure 28E; RM-ANOVA, no 
effect of genotype, F(1,42) = 0.6653, p = 0.4193; main effect of stimulus duration, F(3,126)  = 
7.328, p = 0.0001; no interaction effect, F(3,126) = 0.1218, p = 0.9471), or reward 
collection latency (Figure 28F; RM-ANOVA, no effect of genotype, F(1,42) = 2.952, p = 
0.0931; no effect of stimulus duration, F(3,126)  = 2.271, p = 0.0835; no interaction effect, 
F(3,126) = 0.6320, p = 0.5957). 
The combined data for 7 month-old 5xFAD females revealed a significantly decreased 
accuracy compared to age-matched controls (Figure 29A; RM-ANOVA, main effect of  
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WT Females   n=22 5xFAD Females   n=22
Figure 28. Performance and response measures of the combined data for 4.5 
month-old 5xFAD Females at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (5xFAD females n=22, WT females n=22, data are mean ± SEM) 
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WT Females   n=20 5xFAD Females   n=19
Figure 29. Performance and response measures of the combined data for 7 
month-old 5xFAD Females at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (5xFAD females n=19, WT females n=20, data are mean ± SEM, *p<0.05, 
**p<0.01 and ***p<0.001) 
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genotype, F(1,37) = 6.260, p = 0.0169; main effect of stimulus duration, F(3,111)  = 67.20, p 
< 0.0001; no interaction effect, F(3,111) = 1.551, p = 0.2053). There were no differences 
observed between genotypes in the combined data for omissions (Figure 29B; RM-
ANOVA, no effect of genotype, F(1,37) = 1.692, p = 0.2014; main effect of stimulus 
duration, F(3,111)  = 46.59, p < 0.0001; no interaction effect, F(3,111) = 0.8721, p = 0.4579), 
correct response latency (Figure 29C; RM-ANOVA, no effect of genotype, F(1,37) = 
2.690, p = 0.1094; main effect of stimulus duration, F(3,111)  = 3.767, p = 0.0128; no 
interaction effect, F(3,111) = 3.306, p = 0.0529), or premature responses (Figure 29D; RM-
ANOVA, no effect of genotype, F(1,37) = 1.314, p = 0.2589; no effect of stimulus duration, 
F(3,111)  = 2.078, p = 0.1072; no interaction effect, F(3,111) = 0.0798, p = 0.9709). However, 
combined data for 7 month-old 5xFAD females did demonstrate significantly different 
perseverative correct responses (Figure 29E; RM-ANOVA, main effect of genotype, 
F(1,37) = 11.19, p = 0.0019; main effect of stimulus duration, F(3,111)  = 7.327, p = 0.0002; 
no interaction effect, F(3,111) = 0.2583, p = 0.8552), and reward collection latency 
compared to controls (Figure 29F; RM-ANOVA, main effect of genotype, F(1,37) = 15.12, 
p = 0.0004; no effect of stimulus duration, F(3,111)  = 1.204, p = 0.3117; no interaction 
effect, F(3,111) = 1.085, p = 0.3585).  
Combined data for 10 month-old 5xFAD females displayed a difference in accuracy 
compared age-matched controls (Figure 30A; RM-ANOVA, main effect of genotype, 
F(1,32) = 9.415, p = 0.0044; main effect of stimulus duration, F(3,96)  = 56.68, p < 0.0001; 
no interaction effect, F(3,96) = 0.4453, p = 0.7212). In contrast, combined data for female 
5xFAD mice suggest there was no difference in omission when compared to controls 
(Figure 30B; RM-ANOVA, no effect of genotype, F(1,32) = 2.111, p = 0.1560; main effect  
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WT Females   n=15 5xFAD Females   n=19
Figure 30. Performance and response measures of the combined data for 10 
month-old 5xFAD Females at the University of Western Ontario and at the 
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a 
series of probe trial schedules and the average values of the sessions are plotted. A, 
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean 
premature responses. E, Mean perseverative correct. F, Mean reward collection 
latency (5xFAD females n=19, WT females n=20, data are mean ± SEM, *p<0.05 and 
**p<0.01) 
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of stimulus duration, F(3,96)  = 46.05, p < 0.0001; no interaction effect, F(3,96) = 3.649, p = 
0.153), correct response latency (Figure 30C; RM-ANOVA, no effect of genotype, F(1,32) 
= 0.6071, p = 0.4461; main effect of stimulus duration, F(3,96)  = 9.548, p < 0.0001; no 
interaction effect, F(3,96) = 1.157, p = 0.3301), or premature responses (Figure 30D; RM-
ANOVA, no effect of genotype, F(1,32) = 0.5205, p = 0.4759; main effect of stimulus 
duration, F(3,96)  = 4.009, p = 0.0098; no interaction effect, F(3,96) = 0.3724, p = 0.7731). 
However, combined data did reveal genotype differences in perseverative correct 
responses (Figure 30E; RM-ANOVA, main effect of genotype, F(1,32) = 7.138, p = 
0.0118; main effect of stimulus duration, F(3,96)  = 4.766, p = 0.0039; no interaction effect, 
F(3,96) = 0.6510, p = 0.5842), and reward collection latency (Figure 30F; RM-ANOVA, 
main effect of genotype, F(1,32) = 6.787, p = 0.0138; no effect of stimulus duration, F(3,96)  
= 0.3265, p = 0.8062; no interaction effect, F(3,96) = 0.6618, p = 0.5775).   
  89 
4 Discussion 
4.1 Touchscreen systems diminish reproducibility problems 
associated with animal behavioural testing  
Traditional mouse behavioural testing is usually slow, not amenable to high-throughput 
screening of a large number of animals and is far from being standardized. Unfortunately, 
conventional cognitive behavioural tests for mouse models are subject to extreme 
variation (Wahlsten et al., 2001, Wahlsten et al., 2003, Brown et al., 2009). The 
touchscreen-based 5-CSRTT in this study helped to improve these problems by allowing 
us to obtain replicable data between the two laboratories at site 1 and site 2.  
The touchscreen systems gave us the opportunity to test a high number of animals daily 
and increase our sample size, thus improving statistical power of experiments. Research 
has shown that studies with a small number of subjects have a lower statistical power and 
hence a decreased chance of detecting a true effect (Button et al., 2013). In addition, 
research has revealed the average statistical power of studies in neuroscience is very low 
(Button et al., 2013). The data between site 1 and site 2 showed minimal variation and 
thus allowed us to combine the data within genotypes.  
Traditional mouse behavioural testing also lacks translatable ability from the pre-clinical 
to clinical setting. For instance, multiple promising pharmacological treatments observed 
in animal models of AD failed to show similar results when tested in the clinic (Selkoe, 
2012). The touchscreen systems utilized in this study are far more translatable to humans 
than other traditional mouse behavioural tests, such as the Morris Water maze or the Y-
maze task. Based on the human CANTAB systems, the 5-CSRTT on the mouse 
touchscreen systems examine the same parameters as those observed in humans with AD 
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or MCI, hence increasing the translational potential for research in mouse models of AD 
(Bussey et al., 2008, Romberg et al., 2013a).  The data obtained in this study help to 
provide an important baseline for the onset and progression of attention deficits in the 
3xTG and 5xFAD mouse lines for the testing potential pharmaceutical agents using the 5-
CSRTT in the future.  
 
4.2 Basis of Attention Deficits in AD 
Translation of data from mouse experiments to humans may also be improved if we were 
to expand our scope in preclinical studies to include not only memory, but also other 
relevant cognitive brain constructs such as attention. Individuals with AD have impaired 
executive control, part of which is attention (Perry and Hodges, 1999, Baddeley et al., 
2001). Clinical observation of AD patients has revealed they have difficulty performing 
simple tasks at a relatively early stage in the disease, often described easily distractible, 
unable to concentrate and have difficulty with tasks that were previously easily 
performed (Perry and Hodges, 1999). Recent work from Dr. Bussey and Dr. Saksida’s 
lab has shown the 3xTG male mice, older than 10 months, have deficits in attention using 
the 5-CSRTT on the touchscreen systems (Romberg et al., 2011). The results obtained in 
this study for 3xTG males reproduce those observed by Dr. Bussey’s lab. Other work on 
the TgCRND8 mouse model of AD has shown deficits in attention during the latter stages 
of life (Romberg et al., 2011, Romberg et al., 2013b). Our study demonstrates a 
systematic deficit in 5-CSRTT performance with age in both the 3xTG and 5xFAD 
mouse models of AD. 
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Current evidence suggests that attention is the first non-memory domain to be affected in 
AD before deficits in visuospatial functions and language are observed (Perry and 
Hodges, 1999, Romberg et al., 2013a). Hence, recognizing the onset of attention deficits 
may help in the early diagnosis of AD, before it progresses to other cognitive domains. 
This is an important step in testing potential pharmacological interventions that act early 
and prevent the progression of AD. Different mouse models of AD have attention deficits 
at different ages depending on a number of factors including the types of mutations the 
mice carry (Webster et al., 2014). Our study demonstrated that the onset of attention 
deficits in the 3xTG and 5xFAD mouse models differs, with 4 and 7 months of age 
respectively. More importantly, this helps establish a baseline for the onset of AD-like 
attention deficits in these two mouse models of AD. The majority of behavioural studies 
using these or other mouse models of AD test cognitive functions when the mice are in 
later stages of life, in order to mimic the symptoms of AD seen in humans (Romberg et 
al., 2011, Romberg et al., 2013b). Unfortunately, not only does this increase the costs of 
maintaining mice as they age, but it also decreases the success of potential therapeutics as 
the AD-like pathology may be too far advanced in the older mice.  
 
4.3 3xTG Mice Show Attention Deficits Earlier than 5xFAD  
We show that both the 3xTG and 5xFAD mouse lines exhibit attention deficits using the 
5-CSRTT. The 3xTG male and female mice showed deficits in accuracy, the main 
measure of attention in this task, at 4.5 months of age and throughout the other two time 
points at 7 months and 10 months. On the other hand, the 5xFAD male and female mice 
showed deficits in accuracy starting at 7 months and more statistically significant deficits 
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at 10 months, but showed no difference at 4.5 months. This difference in performance 
could be a result of the additional tau mutation the 3xTG mice carry. The 5xFAD mice 
have three mutations on the APP gene (APPSWE, APPFl, APPLON) as well as two 
mutations on the PSEN1 gene (M146L and L286V) (Oakley et al., 2006). The 3xTG 
mice on the other hand have one mutation for APP (APPSWE), one on PSEN1 (M146L) 
and a mutation on the tau transgene (P301L) (Oddo et al., 2003b). The 3xTG mice show 
accumulation of both plaques and tangles in AD relevant brain regions as well as loss in 
synaptic plasticity and cholinergic receptors (Billings et al., 2005). In the 3xTG mice, the 
first detectable pathology is the development of intracellular Aβ at 3 months followed by 
detection of both extracellular Aβ plaques and hyperphosphorylated tau in the 
hippocampus at 6 months (Billings et al., 2005, Mastrangelo and Bowers, 2008). The 
5xFAD mice however, have been shown to have intracellular Aβ detectable at 1.5 months 
and extracellular plaques at 2 months (Oakley et al., 2006).  
Although many studies have suggested that Aβ is the initiating factor of AD and tau 
dysfunction is a downstream factor to Aβ aggregation (Hardy and Allsop, 1991, Hardy 
and Selkoe, 2002) other studies have suggested that tau interacts with Aβ and accelerates 
the progression of AD (Oddo et al., 2006a). Numerous studies have also shown that 
soluble oligomers are the most toxic form of Aβ to neurons (Harper et al., 1997, Walsh 
and Selkoe, 2007) and several others have shown that soluble tau oligomers may also be 
more toxic in AD (Berger et al., 2007, Roberson et al., 2007, Lasagna-Reeves et al., 
2011, Castillo-Carranza et al., 2014). More recent studies have also revealed that soluble 
tau species including prefibrillar, oligomeric and prefilament forms are more toxic in AD 
than the hallmark NFTs, which may in fact have a more protective role (Bretteville and 
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Planel, 2008, Cowan and Mudher, 2013). Hence, in the 3xTG mice, oligomeric tau 
protein may be leading to the early deficits in attention observed in the 5-CSRTT.  
The AD-like attention deficits observed in both the male and female 5xFAD mice at 7 
months and onwards can be attributed to the mutations in APP and PSEN-1 that lead to 
Aβ plaques. Attentional control, part of executive functions, is controlled by a myriad of 
cortical and subcortical regions. The 5xFAD mice have been shown to have Aβ 
accumulation in cortical regions by 6 months of age, followed by synaptic degeneration 
and loss of neurons by 9 months (Oakley et al., 2006, Bilkei-Gorzo, 2014). This 
coincides with the deficits in attention we observed in the 5xFAD mice, first appearing at 
7 months and deteriorating significantly at 10 months, for both sexes. Thus, the deficits in 
attention observed in the 5xFAD mouse line suggests they are a direct result of Aβ 
accumulating in the cortex.  
 
4.4 Other Cognitive deficits in AD-mouse models revealed 
by the 5-CSRTT 
Similar to the attention deficits observed, the 3xTG mice also showed very significant 
deficits in correct response latency throughout all three probe trials. Correct response 
latency is the amount of time a mouse takes to touch the screen after the onset of a 
stimulus. This is a measure of cognitive processing speed (Romberg et al., 2011) and the 
3xTG mice took significantly longer from the first time point of 4.5 months and onwards. 
The 5xFAD mice also showed deficits in correct response latency but these were only 
present during the later time points. The cognitive processing of the 3xTG mice so early 
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in life can be again attributed to the presence of the tau (P301L) mutation. Recent studies 
have shown that levels of hyperphosphorylated tau protein, NFTs, but not Aβ load, 
correlates strongly with cognition in AD (Giacobini and Gold, 2013). In one study, APP 
mice that showed cognitive deficits were crossed with tau knockout mice to make a new 
mouse mode that lower levels of tau. This had no effect on the development of Aβ 
pathology; however, it did prevent the cognitive deficits that were seen originally in the 
APP mice (Roberson et al., 2007). Findings in studies using transgenic animals carrying 
tau mutations also seem more closely aligned with human AD studies (LaFerla and 
Green, 2012). The 5xFAD mice also showed deficits in correct response latencies but 
during the last probe trials. Evidence from previous research has suggested that Aβ 
formation can drive tau pathology in patients with AD (Handoko et al., 2013). Transgenic 
mice that overexpress mutated forms of APP, like the 5xFAD mice, are the most 
commonly used animal models of AD in research. Despite extensive Aβ accumulation, 
these mice do not develop NFTs, but research has shown that they can exhibit elevated 
levels of hyperphosphorylated tau (Oddo et al., 2006b). This may be occurring in the 
5xFAD mice as well, in the later stages of their life, after extensive Aβ plaque 
accumulation has occurred leading to the deficits in cognitive processing speed that we 
observed during the 10 months time point.  
On the other hand, the 5xFAD mice also demonstrated significant differences in 
preservative correct and reward collection latency during the 10 months probe trial. 
Although food restricted, these mice showed a lack of motivation (higher reward 
collection latency) and were more placid (decreased preservative correct) compared to 
their age-matched wild-type littermates. These deficits at 10 months, along with the 
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deficits in accuracy and correct response latency, may be occurring due to the widespread 
Aβ accumulation that leads to neurodegeneration in these mice starting at 9 months of 
age (Oakley et al., 2006). As previously shown, the 5xFAD mice have extensive Aβ 
deposition in the cortex, subiculum, and hippocampus from 9 months onwards (Oakley et 
al., 2006). At 9 months of age, 5xFAD transgenic mice have only 75% of the neurons that 
age-matched controls possess due to synaptic degeneration (Oakley et al., 2006). Hence, 
this may be the driving factor to the cognitive deficits observed in this mouse line. 
 
4.5 Male 3xTG and 5xFAD mice show increased attention 
deficits with age compared to females 
The male 3xTG and 5xFAD mice showed greater deficits in attention with age compared 
to females. At the last time point of 10 months, the males from both sites demonstrated 
not only deficits in accuracy, but also in omissions. The females on the other hand did not 
show any difference in omission. Although accuracy is the main measure of attention in 
the 5-CSRTT, differences in omission can also represent deficits in attention as it 
determines whether there is a complete failure to pay attention the stimulus displayed on 
the screen (Romberg et al., 2013a). Thus, the males from both mouse lines seem to have 
greater AD-like cognitive deficits in attention at this age than females.  
Research has suggested that estrogen, the female sex hormone, can play a protective role 
in the brain of females against AD, and loss of estrogen during menopause leads to 
deficits in brain metabolism leading to the hallmark lesions seen in the disease (Long et 
al., 2012). Estrogen has also been shown to have a critical role in neurogenesis in various 
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regions including the hippocampus and other subcortical regions leading to the 
generation of neurons that contribute to region-specific learning and memory (Galea et 
al., 2013). Several studies have provided insight into the importance of estrogen on 
neuronal morphology and synaptic plasticity in the CA1 region of the hippocampus 
(Mukai et al., 2010, Hojo et al., 2011, Ooishi et al., 2012, Spencer-Segal et al., 2012). 
Moreover, estrogen reduces levels of Aβ in the presence of pathological triggers 
(Anastasio, 2013). Research has also shown that estrogen can help reduce levels of Aβ 
production by decreasing BACE1 enzyme levels, and increasing Aβ clearance by 
stimulation of microglia degradation and phagocytosis as well as increasing levels of 
other enzymes that are involved in Aβ degradation (Singh et al., 1999). Additionally, 
studies have also shown that estrogen has a role in decreasing levels of 
hyperphosphorylated tau by activating kinases and phosphatases such as the Wnt, GSK-
3β and PKA pathways (Zhang et al., 2008). The loss in estrogen during menopause in 
females has been suggested to account for the increased susceptibility to AD compared to 
males (Yue et al., 2005, Li et al., 2013). Furthermore, one study demonstrated decreased 
levels of estrogen in the CSF of AD patients providing additional confirmation of its role 
in the disease (Schonknecht et al., 2001).  
Moreover, in a recent study that used aged female 3xTG mice, there was an increase in 
AD pathology in transgenic mice who had an overiectomy, leading to reduced levels of 
estrogen and other gonadotropins, compared to age-matched transgenic females that did 
not (Palm et al., 2014). In addition, research shows that levels of estrogen and 
testosterone decrease steadily with age in both males and pre-menopausal females 
(Ferrini and Barrett-Connor, 1998). Thus, the attention deficits in the mice at 10 months 
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may also be due to a slight decrease in levels of estrogen with age, leading to an increase 
in AD-like pathology. Overall, our study suggests estrogen may be playing a protective 
role in both the 3xTG and 5xFAD female mice. The lower levels of estrogen in males 
may be contributing to greater AD-like pathology thus leading to greater attention deficits 
with age.  
 
4.6 Conclusion 
In summary, we provide a good baseline for the onset and progression of AD-like 
attention deficits in both the 3xTG and 5xFAD mouse lines. Due to their three mutations 
that lead to both Aβ plaques as well as tau NFTs, both the male and female 3xTG mice 
showed deficits in attention during the first time point and onwards of this longitudinal 
study. The 5xFAD males and females on the other hand, with their five additive 
mutations that lead an accelerated rate of amyloidosis, showed deficits from the 7 months 
time point and onwards. In addition, the majority of data was reproduced between site 1 
and site 2, attesting to the reliability of the touchscreen systems used in this study. 
Transgenic male mice from both lines showed greater deficits in attention with age 
compared to female mice.  
 
4.7 Future Directions 
Further behavioural testing will be done using both the 3xTG and 5xFAD mice on the 
touchscreen systems to determine if and when they have deficits in other cognitive 
domains. The PAL task will be utilized to test for spatial memory deficits and the PD task 
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will be used to evaluate whether the mice have deficits in extinction learning. In addition, 
another mouse model of AD, the APP/PSEN1 male and female mice will be used on all 
three touchscreen tasks (5-CSRTT, PAL, and PD) to determine whether they also display 
AD-like cognitive symptoms. Furthermore, we plan on imaging the brains of all three 
mouse lines at the three probe trial time points used in the 5-CSRTT in order to determine 
the extent of AD-like plaques and tangles these mice display. In the near future, we also 
plan on testing potential pharmacological agents that may help treat the cognitive 
symptoms associated with AD using the touchscreen systems and the baselines 
established in order to accelerate this process.  	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TITLE: 5-Choice Serial Reaction Time Task (5-CSRT) 




The 5-CSRT task has been designed to measure effects of drugs and other manipulations 
(ex: genetic) on attentional performance (and stimulus control). The test is performed in a 
specially designed touchscreen-based automated chamber with multiple response 
locations (’five-windows”) using food reinforcers to maintain performance. The 5CSRTT 
is useful for measuring effects of different manipulations on various aspects of attentional 
control, including sustained, selective and divided attention – and is relevant to the 
definition of neural systems of attention and has applications to human disorders such as 
attention deficit/hyperactivity disorder (ADHD) and Alzheimer’s disease.  
 
2.0 EQUIPMENT	  
- Mouse	  Touch	  Screen	  Systems	  and	  ABET	  II	  	  
- 89543CAM	  	  5-­‐Choice	  Serial	  Reaction	  Time	  Task	  with	  Cambridge	  Amendment	  
- 	  
3.0 PROCEDURE	  	  
	  
3.1 Testing	  the	  hardware:	  
A quick test of the hardware should be done prior to every days training or 
testing. To do the hardware testing, follow procedures indicted below: 
a. From the main menu the Execution Manager, select the boxes you wish to test. 
b. Click the ‘Open/Load Schedule’ icon and select ‘Touch MouseTestLines’ and click 
‘Open’. 
c. Click the play icon. The boxes are now ready to test.  
 
  
See Table 1 for Inputs to activate a response and output response expected.  
 
Table 1: Action necessary and output response expected. 





Touch	  Grid	  1	   Image	  in	  all	  grid	  spaces,	  Grid	  1	  has	  
30%	  
of	  full	  white,	  grids	  2	  to	  4	  have	  full	  
white	  
image.	  
Activate	  the	  Tray	  to	  clear	  all	  images	  
and	  proceed	  with	  test.	  
	   Touch	  Grid	  2	   Image	  in	  all	  grid	  spaces,	  Grid	  2	  has	  
40%	  
of	  full	  white,	  all	  other	  grids	  have	  full	  
white	  image.	  
Activate	  the	  Tray	  to	  clear	  all	  images	  
and	  proceed	  with	  test.	  
	   Touch	  Grid	  3	   Image	  in	  all	  grid	  spaces,	  Grid	  3	  has	  
50%	  
of	  full	  white,	  all	  other	  grids	  have	  full	  
white	  image.	  
  
Activate	  the	  Tray	  to	  clear	  all	  images	  
and	  proceed	  with	  test.	  
	   Touch	  	  Grid	  4	   Image	  in	  all	  grid	  spaces,	  Grid	  4	  has	  
70%	  
of	  full	  white,	  all	  other	  grids	  have	  full	  
white	  image.	  
Activate	  the	  Tray	  to	  clear	  all	  images	  
and	  proceed	  with	  test.	  
	   Touch	  	  Grid	  5	   Full	  white	  (bright)	  image	  in	  all	  grid	  
spaces.	  Pulses	  Sound_On	  500ms	  
Activate	  the	  Tray	  to	  clear	  all	  images	  
and	  proceed	  with	  test.	  
	   Enter	  the	  feed-­‐tray	   House-­‐light	  and	  tray-­‐light	  illuminate	  
and	  	  feeder	  -­‐	  800ms	  
	   Exit	  the	  feed-­‐tray	   Houselight	  and	  tray	  light	  extinguish	  
	   Block	  Front	  IR	  activity	  
beams	  
House-­‐light	  illuminates	  





3.2 Testing	  the	  feeder	  and	  mask	  
  
- A	   quick	   test	   of	   the	   feeder	   should	   be	   done	   prior	   to	   every	   days	   training	   or	  
testing.	  That	   is,	  turn	  on	  manually	  the	  switch	  on	  the	  feeder	  pump	  and	  make	  
sure	  the	  food	  is	  delivered.	  	  
- Make	  sure	  the	  5CSRT	  Mask	  is	  inserted	  (5	  windows).	  
- Reward	  provided	  is	  Neilson	  Strawberry	  milkshake	  (SM)	  (Saputo	  Inc.	  Montreal	  
Quebec.	   H1P1X8).	   This	   milkshake	   can	   be	   found	   in	   most	   grocery	   stores	  
(including	  Wall	  Mart	  and	  Superstore).	  
	  
3.3 Pre-­‐training	  
- Animals	  need	  to	  be	  food	  restricted	  before	  task	  training	  and	  throughout	  
experiment	  (see	  relevant	  SOPs:	  “Food	  restriction	  in	  young	  mice”	  or	  “Food	  
restriction	  in	  adult	  mice”).	  	  
- Divide	  the	  subjects	  of	  each	  group	  to	  be	  tested	  (Ex:	  Group	  1:	  5xFAD	  females,	  
Group	  2:	  APP	  males)	  into	  4	  sub-­‐groups	  (A,	  B,	  C,	  D).	  Groups	  must	  be	  counter-­‐
balanced	  for	  genotype	  (wt	  x	  mutant).	  Each	  subgroup	  is	  going	  to	  follow	  specific	  
testing	  schedules	  during	  probe	  trial	  (see	  Table	  2).	  
 
3.4 Training	  Procedures	  
	  
3.4.1 Basic	  training	  schedule	  	  
 
IMPORTANT: for both training and probe trials, each mouse is submitted to one session 
per day. 
 
Stage 1: Habituation1: 1 session. Load the habituation1 schedule from the CAM-
5choice subdirectory in the ABETII software. The session duration is set to 600s (10 
minutes), and the number of trials is left to unlimited. Mouse is left in the chamber for 10 
min. All lights are turned off. No stimulus or reward is presented. It is critical that the 
mouse is removed from the cabinet as soon as the habituation is complete.   
 
Stage 2: Habituation2a: 2 sessions. Load the habituation2 schedule from the CAM-
5choice subdirectory in the ABETII software. The session duration is set to 1200s (20 
minutes), and the number of trials is left to unlimited. The mouse is left in the chamber 
for 20 min sessions. The tray light is going to be initially turned on. A tone is played and 
the food-tray/magazine is primed with strawberry milkshake (SM) delivered for 6000ms 
(150µl). The program waits for the mouse to enter the food tray. When the mouse leaves 
the reward tray, the reward tray light is turned off. There is a 10s delay before the tray 
light is turned on, a tone is played and SM is then delivered for 280ms (7 µl). If the 
  
mouse is in the reward tray at the end of the 10s delay, an extra 1s is added to the delay. 
The procedure is repeated until the session ends. 
 
Stage 3:  Habituation2b:  1 session.  Load the habituation2 schedule from the CAM-
5choice subdirectory in the ABETII software. The session duration is set to 2400s (40 
minutes), and the number of trials is left to unlimited. The mouse is left in the chamber 
for 40 min. Reward presentation is the same as described in stage 2. It is critical that the 
mouse is removed from the cabinet as soon as the habituation is complete. 
 
Stage 4:  “Initial touch”: (usually 1 session). Load the schedule ‘5-choice Mouse Initial 
Touch Training’ from the CAM-5choice subdirectory. Set the Session: 
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure 
that “Image Time” is 30s; ‘Feed Pulse Time” is 280ms; “tone duration” is 1000 ms, and 
ITI period is 5s. The stimulus (a white square) is displayed randomly in one of the 5 
windows. The stimulus is presented in only one window at a time. The other windows are 
left blank. The position is chosen pseudo randomly, such that the stimulus will not be 
displayed in the same position more than 3 times in a row. After a delay (Image Time – 
30s) the image is removed and food is delivered (‘Feed Pulse Time –280ms). Food 
delivery is accompanied by illumination of the tray light and a tone. The tone frequency 
is 3 KHz. The tone duration is (1000 ms). Entry to collect the food turns off the tray light 
and starts the ITI. After the ITI period (5s) another image is displayed. If the mouse 
touches the screen whilst the image is displayed (where the image is displayed), the 
image is removed, a tone will be played and 3 x food is delivered immediately. 
Collection of this reward again starts the ITI and then progresses to the next image. 
Touch training is performed with the house light off.  
Criterion:  Completion of 30 trials within 60 min. Repeat sessions until criterion is 
achieved. 
 
Stage 5: “Must touch”: Number of session varies for individual mouse.  It can go from 
~1-7 days (median: 2 days). Run the schedule ‘5-choice Mouse Must Touch Training’ 
from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to 60 
minutes, i.e. 60:00. Set the Max No Trials to 30. Make sure tone duration is set to 1000 
ms (from the ‘Tone Duration’ variable) and ITI period is set to 5s. 
The stimulus (a white square) is displayed randomly in one of the 5 windows. The 
stimulus is presented in only one window at a time. The other windows are left blank. 
The position is chosen pseudo randomly, such that the stimulus will not be displayed in 
the same position more than 3 times in a row. The mouse must touch the stimulus to elicit 
tone/food response. There is no response if mouse touches blank part of the screen. Food 
delivery is accompanied by illumination of the tray light and a tone. The tone frequency 
  
default is 3 KHz. Entry to collect the food turns off the tray light and starts the ITI. After 
the ITI period (5s) another image is displayed. 
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is 
achieved. 
IMPORTANT: If after 7 sessions a mouse does not reach criterion for “must touch”, 
take it back one step; that is,  retrain the mouse on “Initial touch” until it reaches criterion 
and repeat the “Must touch” training. If after 7 sessions of the second attempt of “must 
touch” the mouse does not reach criterion, remove it from the study.  
Stage 6:  “Must initiate”: Number of session varies for individual mouse. It usually 
takes ~1-2 sessions (i.e. 1 or days). Run the schedule ‘5-Choice Must Initiate Training’ 
from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to 60 
minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure tone duration is set to 1000 
ms (from the ‘Tone Duration’ variable) and ITI period is set to 5s.  
A free delivery of food is made and the tray light is turned on. The mouse must nose poke 
and exit the reward tray before a stimulus is displayed randomly on the screen. The 
stimulus (a white square) is displayed randomly in one of the 5 windows. The stimulus is 
presented in only one window at a time. The other windows are left blank. The position is 
chosen pseudo randomly, such that the stimulus will not be displayed in the same 
position more than 3 times in a row.) The mouse must touch the stimulus to elicit 
tone/food response. There is no response if mouse touches the blank parts of the screen. 
Food delivery is accompanied by illumination of the tray light and a tone. Entry to collect 
the food turns off the tray light and starts the ITI. After the ITI period the tray light is 
again illuminated. The mouse must nose poke and exit the reward tray before the next 
image is displayed.  
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is 
achieved. 
IMPORTANT: If after 5 sessions a mouse does not reach criterion for “must initiate”, 
take it back one step; that is, retrain the mouse on “must touch” until it reaches criterion 
and repeat the “Must Initiate” training. If after 5 sessions of the second attempt of “must 
initiate” the mouse does not reach criterion, remove it from the study. 
Stage 7: “Punish incorrect”. Number of session varies for individual mouse. It can go 
from ~2-30 days (median: 9 days). Run the schedule ‘5-Choice Mouse Punish Incorrect 
Training’ from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to 
60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure tone duration is set to 
1000 ms and ITI period is set to 5s. 
  
This schedule trains the mouse to both initiate after an ITI and not to touch an incorrect 
location. As for previous training described above, except if a mouse touches an incorrect 
(non-illuminated) location the house light will be turned ON for 5s and no reward is 
given. Once the time out period finishes the house light is turned OFF again and the ITI 
period begins (5s). The mouse must then complete a correction trial: the image and 
position from the previous trial are kept the same and the mouse must repeat the same 
trial until a correct response to the image is made, at which point it will receive a tone 
and reward. 
Criterion: Completion of 23/30 trials or better within 60 min for 2 consecutive sessions      
IMPORTANT: If after 30 sessions (30 days) the mouse does not reach criterion for 
“Punish incorrect”, remove it from study.  
3.4.2 5-­‐CSRT	  Training	  to	  baseline	  
Stage 8: 5-CSRT training to baseline- 4s stimulus. Number of session varies for 
individual mouse. It can go from ~4-30 days (median: 11 days). Run the 
‘5CSRTT_4s_Var1’ from the CAM-5choice  subdirectory schedule. Set the Session: 
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 50. Make sure 
tone duration is set to 1000 ms, ITI period is set to 5s, Food/CM pulse time [280ms (7 µl 
SM), Delay interval (5s), time out (TO, 5s) and ITI Incorr (5s). 
 
 The session begins with a priming delivery of reinforcer [280ms (7 µl SM)] and on 
exiting the food magazine the first trial begins. Following tray exit, a “Delay interval” 
(5s) begins at the end of which a stimuli is presented in one of the 5 stimuli grid spaces 
on the LCD touch screen. The sequence of presentations of the stimuli is a pseudorandom 
schedule such that there are 4 presentations at each spatial location within a block of 20 
trials. The subject must respond within a time period defined (limited hold period 5s). A 
correct response, touching at the location in which the stimulus was presented, will 
trigger the presentation of reinforcer [280ms (7 µl SM)] into the food magazine. Food 
delivery is accompanied by illumination of the tray light and a tone. The tone duration is 
(1000 ms tone). The subject collects the food by making an entry at the food magazine. 
On exiting the food tray the ITI (5s) will begin. After the ITI period, the tray light comes 
on again and the mouse must enter and exit the food tray to start the next trial and start 
the Delay’ interval. An incorrect response, i.e. touching a location other than where the 
stimulus was presented, or making no response at all (an omission) within the limited 
hold period, will cause a time out (TO, 5s) as identified house light turned ON. After the 
TO, the house light will be turned OFF and the “ITI Incorr” will begin (5s). After the 
ITI incorr period the tray light will come on and the subject must enter and exit the food 
tray to start the next trial and start the Delay’ interval. A premature response is recorded 
when a touch is made in one of the response grid areas during the Delay and also results 
in a TO. 
  
> 80% accuracy = [number of Correct trials / Total number of trials responded to (correct 
and incorrect)] 
< 20% omissions = [number of trials missed / number of trials presented] 
 
Criterion:  80% accuracy or better, 20% omission or less, 3 consecutive days, minimum 
30 trials completed per session. 
 
Stage 9: 5-CSRT training to baseline- 2s stimulus. Number of sessions varies for 
individual mouse. It can go from ~5-30 days (median: 12 days). Run the 
‘5CSRTT_2s_Var1 schedule from the CAM-5choice  subdirectory. Set the Session: 
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 50. . Make sure 
tone duration is set to 1000 ms, ITI period is set to 5s, Food/CM pulse time [280ms (7 µl 
SM), Delay interval (5s), time out (TO, 5s) and ITI Incorr (5s). 
The session begins with a priming delivery of reinforce [280ms (7 µl SM)] and on 
exiting the food magazine the first trial begins. Following tray exit, a “Delay interval” 
(5s) begins at the end of which a stimuli is presented in one of the 5 stimuli grid spaces 
on the LCD touch screen. The sequence of presentations of the stimuli is a pseudorandom 
schedule such that there are 4 presentations at each spatial location within a block of 20 
trials. The subject must respond within a time period defined (limited hold period 5s). A 
correct response, touching at the location in which the stimulus was presented, will 
trigger the presentation of reinforce [280ms (7 µl SM)] into the food magazine. Food 
delivery is accompanied by illumination of the tray light and a tone. The tone duration is 
(1000 ms tone). The subject collects the food by making an entry at the food magazine. 
On exiting the food tray the ITI (5s) will begin. After the ITI period, the tray light comes 
on again and the mouse must enter and exit the food tray to start the next trial and start 
the Delay’ interval. An incorrect response, i.e. touching a location other than where the 
stimulus was presented, or making no response at all (an omission) within the limited 
hold period, will cause a time out (TO, 5s) as identified house light turned ON. After the 
TO, the house light will be turned OFF and the ‘ITI Incorr’ will begin (5s). After the ITI 
incorr period the tray light will come on and the subject must enter and exit the food tray 
to start the next trial and start the Delay’ interval. A premature response is recorded when 
a touch is made in one of the response grid areas during the Delay and also results in a 
TO. 
Criterion:  80% accuracy or better, 20% omission or less, 3 consecutive days, 50 trials 
must be completed per session. 
 
 
3.4.3 Testing	  schedules	  
  
Stage 10: First probe trial evaluation. Subjects will not progress through the training at 
exactly the same rate. The first set of probe trials for a group begins once the last mouse 
in that group has passed the 2s stimulus performance criteria (Stage 9). Subjects that have 
completed the Stage 9 before the slowest subject are maintained on food restriction and 
repeat Stage 9 before performing their probe trial. There is no minimum performance 
criterion for subjects to advance through the probe trials. The order of performance of 
probe trials for each counter-balanced group varies according to Table 2. 
- For	  the	  2s	  stimulus	  run	  the	  ‘5CSRTT_2s_Var1schedule	  from	  the	  CAM-­‐5choice	  	  
subdirectory.	  Set	  the	  Session:	  Max_Schedule_Time	  to	  60	  minutes,	  i.e.	  60:00.	  Set	  
the	  Max	  No.	  Trials	  to	  50.	  
- For	  the	  1.5s	  stimulus	  run	  the	  ‘5CSRTT_1.5s_Var1schedule	  from	  the	  CAM-­‐5choice	  
subdirectory.	  Set	  the	  Session:	  Max_Schedule_Time	  to	  60	  minutes,	  i.e.	  60:00.	  Set	  
the	  Max	  No.	  Trials	  to	  50.	  
- For	  the	  1s	  stimulus	  run	  the	  ‘5CSRTT_1s_Var1schedule	  from	  the	  CAM-­‐5choice	  	  
subdirectory.	  Set	  the	  Session:	  Max_Schedule_Time	  to	  60	  minutes,	  i.e.	  60:00.	  Set	  
the	  Max	  No.	  Trials	  to	  50.	  
- For	  the	  	  0.8s	  stimulus	  run	  the	  ‘5CSRTT_0.8s_Var1schedule	  from	  the	  CAM-­‐5choice	  	  
subdirectory.	  Set	  the	  Session:	  Max_Schedule_Time	  to	  60	  minutes,	  i.e.	  60:00.	  Set	  
the	  Max	  No.	  Trials	  to	  50.	  
- For	  the	  	  0.6s	  stimulus	  run	  the	  ‘5CSRTT_0.6s_Var1schedule	  from	  the	  CAM-­‐5choice	  	  
subdirectory.	  Set	  the	  Session:	  Max_Schedule_Time	  to	  60	  minutes,	  i.e.	  60:00.	  Set	  
the	  Max	  No.	  Trials	  to	  50.	  
 























sessions	  for	  	  
Sub-­‐group	  D	  
  
2	   0.6s	   0.8s	   1.0s	   1.5s	  
2	   2.0s	   2.0s	   2.0s	   2.0s	  
2	   1.5s	   0.6s	   0.8s	   1.0s	  
2	   2.0s	   2.0s	   2.0s	   2.0s	  
2	   1.0s	   1.5s	   0.6s	   0.8s	  
2	   2.0s	   2.0s	   2.0s	   2.0s	  
2	   0.8s	   1.0s	   1.5s	   0.6s	  
  
Table 3: Setting adjustment for additional variables in probe trials 
Variable	   Value	  
Session	  Length	   60	  min	  
Food/CM	  pulse	  time	   280	  ms	  
DELAY	   5s	  
Time	  out	   5s	  
Limited	  Hold	  Value	   	  5s	  
 
 
Stage 11: Reusing same mouse cohort for a new probe trial  
- All subjects are maintained on food restriction for 1 month.  
  
- Subjects perform one 2s stimulus trial per week during the interval between probe trials. 
 
Stage 12: Second probe trial evaluation 
 
- Mice should be re-baselined at 2s (Stage 9: >80% Accuracy, <20% 
omissions). Depending on how long it’s been since the previous probe trial it 
might be necessary to rebaseline them at 4s first (Stage 8). If they are not re-
baselined the second probe trial will not be accurate. 
- A	  second	  probe	   trial	   should	  be	  performed	  according	   to	   the	  order	   shown	   in	  
Table	  4.	  	  























sessions	  for	  	  
Sub-­‐group	  D	  
2	   1.5s	   0.6s	   0.8s	   1.0s	  
2	   2.0s	   2.0s	   2.0s	   2.0s	  
2	   1.0s	   1.5s	   0.6s	   0.8s	  
2	   2.0s	   2.0s	   2.0s	   2.0s	  
2	   0.8s	   1.0s	   1.5s	   0.6s	  
2	   2.0s	   2.0s	   2.0s	   2.0s	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